SHHEKthRAAaENSSsn AGAR (2007) PREFSCRRFDS ‘1EEMLIEHENGBAT (chronic obstructive pulmonary disease, COPD) 2— FETT SLA HENE I RAO, URS. TEA, POR em RNA FAURE. 2002 AE DAA CWHO) AA ROYER, COPD $A HOTA ETHOS 5 MP. BLES 2020 4F, COPD RW 3 WET COPD AHEM CAECOPD) #3 F OR FEIG FE FB COPD AB 2 E BER BE AY SRAL. NFR AECOPD ABE» PSH EES ULM ER AO LFF, i AECOPD 4 JF RFE HHO BR AA LR. UE, IR LL Dui CiAIF AECOPD Hee 7 EVER, BAO T Bk IF i. WALGER AECOPD SLA AIAIT MARIE. HE BEES Mae EAE ee PEEPS 19 18] PA SPE Rt a AH ARR HAS HE PEEL CA 2001 4E ISP HEA Delphi 33th G1). HAT Be BANE DERE TT ALLE RIP MLS BUR, HERE RL UL AO HERESNIHEIA Del- phi 5} A~E SR, Teh A SORES. 31 Delphi ae EDR A BOR 2 BARRE B MA 1 SRR cS QS 1 BARRE ° BOS 1 AIDRARSREG € RAV ASV SR ARRON, I AREA, YW, SICA, PRIA OCR ROU UME I JIMER, SESUAR, SIS 7HUE, PUBNO Ch) BIBMARERES 0 FENWL, BRAT WV FNL, HP NBATOSRAD v FAROE, EVRA SREM 161162 BARBIE TERE OR —, COPD Pr ac*F 3 5h Ay Jy HE SB AL COPD JAA SE RARE ABO, FCS MANE TBE. eae PERE, GAARA AE ASAT RL EES AE Se EI AS SHERMER BRAM, TERA CAB >2~4mm) ER BCE yHpR SAUL AUBERT. SAYRE BRD ORIR J, APA ERR. GPR AEH Dy WARK By HAS CAGE < 2mm) YE BERR EE. UBL TSE, HERE WP SUPRHOHEMY , HA TRAE AR, TURE RR I. Feu. MSE A CORUM SE. MYL. AE SALE ER PE el aE BE AE TE CHR AOIR H E , AES. BBN AE AE COPD AB AEF tt MERE, CEE TTA IAPR IME a AR eT ak AS HL BE IE Cy namic pulmonary hyperinflation, DPH)"®", AA DPH W9fe¢e. baz PERRIER, FUR A-A UMRAO, RAMI AR ie EAA Ra. SATB A Hh SBC. DPH bf OER A PL HAE S.A MLA SE IEE BY HEIPACARIEHE Cintrinsic positive end-expiratory pressure, PEEPi) "2, fT PEEPi ff 7E. ARAL SPE AR A 0 VA Sel PEEP: eT ELE FEAR FAA MDP ERATE + BIE TW aE. AB AE Ae LB SLED TK, SEAR AUR ER PEP ie MR ES, DA TIT ICA ROR PEAK, AA DIOP UR WL SOF BR, (ELAN NER URC AE He. AI. AE BRABH, WEIN TPR EE COPD SE dn Bef VP Hy eG EAE IAL PEER Of SRO, RESTP OIL A SACRE 7a HLS EER Aa HL “A A CO. WER. TA AE PR EN. COPD Sete A SLR FRR EERE. MARK. AISA, AUR, ZORA. LAR AL. 18 ER HC SEA BR APSE 1) ee LIE GF APRS | YEA Nr AG KA. TERRA LG AAD ERAGE: BCAA, GESTED ei. Jw DPH BRR ARENT, SH BE AT AGE DAA PBL SH CEE OO tor ST eh Ag a id a AR 4 AECOPD ANH, BAH TAAE. WOR AB AIM RY, PYRG WAL REIE AS PAPI 5 TOL SEP BOF OBE AY SE ET. HIBS LA 0 ATE Fe BLPLIL (noninvasive positive pressure ventilation, NPPV) /J-FHU0T aki BUSTER, PRES EA HT REPRE A TAT 4 OIERE EDF EEN SO RG ISRS (2007) 163 HEBLARIEAL (invasive positive pressure ventilation, IPPV) LIAS 385 | TERE REA BEEBE NPPV BEPC. SEAT RR RC A A FAH, FEO EA RRL. PORTA AEE Bt, Ai BEIPPV. ath] NPPV VA dif BASE AL — 3 2 AR ISG, SEER A. AT FEAF BL TT ZAR, ELOY AECOPD @LAE AINSI AE. =. KEE RRA NPPV 22 RAG, ORS Cfull face mask) SAGEIHE Tr AS EULA TT IE a SRA ST MED URE EN, ALO MATT. NPPV HTB AECOPD ff) ET aR. LEBER TAL BE IEEOS , (—) JASE SABIE 1. SUE BI RCT 2 ASAE SPH SAS han. FABLE HL, NPPV Si FAY AECOPD QDR ATIS 80% ~85%, HAA BUM A BL NPPV TAIT BY ERAT IA PY GHA 1~6 -t) GEE pH HH, PaCO, ER. OF ORE MERE SEP ME. HAST HDT BRA A EEE. SE EE BAT el. lath, NPPV RIPE 34 AECOPD (4 — S08 SLIBAIF F Be. TRI] NPPV nk Dy 3% AIA 93%, HEIR NPPYV (4) RDI IUB I 67269) , ‘An fl FE 3S 9 HH AETT NPPV, JERI AE FA NPPV ARBRE. NPPV FARM PAE) AECOPD Ata ebi A. AN HASLNEA NPPV 223iR IPPV fit BL, Ak, BAILA 47 NPPV (9 —2ed AR aE, SOR. MARAE HAA ERA AEH EMRE MAL NPPV HRB WEE Ge 2ee 32 NPPV BURA AECOPD BURA Biren ACER, MAS, S-EVKSIDLRED SRP AED FD RSE REE TR mms BOUL) BHM SOWA BI RCT OSE HP BE OP ERR BE (7. 2525 YK/s}) FY AECOPD, 5 MLAS ABEL, NPPV URGE T BRITA. Fee AE BP oe CNPPV Si Est Ta i FA164 BRUISE SRY eR JEP VA MERE AR ALS ASAE ARE «CSD. PEER MAE Bre SAT ER. BEA /ICU WER. FEBE/TE ICU ATT) ATW ee. Bardi) Ba 1 AEROBIE PERL NPPV TAFT FT RA 1 EATER. Xt pH=7. 35 ff) AECOPD AY, HF RGA ADEM AT, PaCO, Zb-P RE MAY, PH ALF AREE, HRM MARA PRE. MLL 9p. BGT ¢e 65 5 FI NPPV S497 AECOPD iS RCT AE MARE TILA Ta Beas. EF pH >= 7. 35 AR. TEA BENG 2 Abt BDAY Hy LOD REA. AFL Sl, Fa EA EE Be OF HAWG REG (2. 8%vsll. 3%, P—0.047), (ESHER AT ES NPPV FLD (IH PAROLE WB URE IF BG LLP WE SI HAN Se aE — A SBA SEE KU, SWRA. NPPV xt3028727E DPH HRA. ATLA ERA ik THs PSE RE NP RULE Is Fle Hi RE AY OY Xt AECOPD irc HE A Fes PR PENT REM RA. AMER UO NPPV 6 SUE A FE Ta 8 BE Fe, ERISA FT PPV BT BE SEO ABR) EE RCT "Ft, 49 BS RLF FERC tH RL EY ER PEAY AECOPD #84 (pH 7,200.05, PaCO,85mmHg+16mmHg) #%4}29 NPPV 41 Al IPPV “1, 245% BAA BA ASC BH SS. PLR UTA). HP Ae ee fE ICU ff fa], 1CU Fai St 38 ABE AIS SEE AB ILO. TEAR aE EO PE AY 6 fi) AECOPD # # (pH7.18 + 0.05, PaCO;10mmHg + 14mmHg) 4 ii FB NPPV, 3) i) 5 7™ BABE BER (DLE BEET IPPV fy 64 $i] AECOPD A ETT FANT RUG IE, NPPV 4.45 40 (LR RKO PPV, sat. BLE St f. EICUNM EMAAR SEER, AAMT ARO. FREE, ERSTE R AP ORE. HB AAS FLA (8FA NPPV fe AR ET BEBE EDT SEZ Ib. SEL AB CE ALA LE tHE ICU AEAT, {1 NPPV RCE DG BER (25% ~ 63%)", TR GCS<11 4}, APACHE [] >29 4h. PRS > 30 we/S>. IFA pH<7. 25 fy ARATE NPPV JR SBC FT REVERE 50.267), BU. PR RRR EOF OR RE SERA. TER BEIGE US 8 PF AL a PE, CE EB FA NPPV. (AUF 1~2 JI} FE 8H SB AEM I CA IPP”), PF SUE POF a ae AR. FEAT 153 Bi] COPD ABET 5 ERY TAA FEI AL. MRE A PY EAR CKelly-Matthay JFK F 3 Dy), HOPESEAEI GTA 50%, BART TESA EP A] NPPV) “4 IPPV eta UBB / FUR AB ae A TE FR UI}, NPPV AJ E— 2h DRG PIG RI, WAS THEA AECOPD WD AT IS 50% ~ 60%",ERMA SISNET (2007) 165 PP HAY COMBI. MIRED, PAL, SRS APT Fe a F NPPV. WEL 1, NPPV& AECOPD HFA FIR. (AW) AER 2: sf AECOPD SHAM NPPV at, BRSBIR, RRMA, Sih Bh A EAR A Ao LIMB MBCA A. CE BD MAEM 3: THR (Sk pH>7.35, PaCO, >45mmHg) 4 AECOPD & 4% 8-F91 8 NPPV, (CA) REELS, ATR eS PH (7. 25 25cemH.0 A ORE RARE RIUM, RAMS. AVE BIKA, AER FRA PAE: ERROR A RESID 25cmH,0, CE ETE Slot» TAUB NPPV. C2) PRO: FMA RB AP By BRO dR AT A | ESAT BRS UN EEE SPW. MERAH, BAEK, ) ORATH: STARR RAAB, ROR IL. SRST. CA 5 7S ERI OAS 09 EA) CO A SS 2S AR, LOT AIAG. PRT. KRABI, SARS AKT FEE ATs LARAMIE. PACE BOR SE AE Th RAY SO ie. CA) TREE 10 A TT EL a = PE AT ee Be SL), HEL eT 2 (Be FAD A AR A MS SH AY OI 7) HEHE THER AD) TTBS HRI AR, UR RE We th Lee Thy FE BEFEIA ACA a] HEHE 51. TED UCHS TP Ta BR a FG iF AS PRL 2 1 BEET — OC. PTDL et Bee. Hh, RE ER AEB TS AUT LALA BIEBER LA a yO) (5) HES BEDE; NPPV 5y SBS ih ta LEE RE HIE PRE, EES A BAL RK, SRA RR, ERA LAR RE FRSA SE. AE TER BMRA. DRAUUCK. BEAD AE BER AOS sh ha. MLR ESO CHES LER TE), GEES MO. IL Sh, HRY ETT AB On BT LE BB AHI, PPV AR LE PE OA TE HE Chk170 Werte Bike eat WR. VERE. (6) RA CAAT): ABS) AP RTL, ICC A TH BE A SPRURIK AL ARES NPPV G97. 30 ACP AE REE A BE A UP H AR 2F OHA NPPV id. AA PRE Se A fe ELE CD AUR: SF AIA OR. DER RAN At. ARE LEAP IE OR OL CE BE UR. REIL 9: # AECOPD & J) NPPV i647 090 G0 Man) EM Hh A Ae A, REE GARAAREHAR, 2~A MGA, UF RAR Baw, (DR =. Al ER AURA (—) i ReLE x}F AECOPD A%. FU NPPV fF BUH Swe > 7 IPPV ff, {AX TA NPPV *8.S aU] NPPV SMe PEER SERS A. EL AOPPOUB ER. SI, MSA. UTR IPPV. SATE AE RA, 4 AECOPD BS (THA ERM AVEMIE eBREDWAALE (Pade \F 60mmHe 3 PaO, FIO <200mTHe) © PaCO, HATHA RAP BOP (CH<7, 20) co PEARS (ME, BKTES) oP SMURA BER CRIME >10 N/A, PRPRS) ROPMGl (OOPCIAR <8 R/) ° DAMS ARE ° SEOUL ES AR, VRP AERA NPV OFA MNT EURRBES (> ATA MES AECOPD A447 IPPV ih}, ATLAGH ne ue CP. SOU Wie 12 dR ZA UEMENA CE. AACE, RMB, Raa OR, MAREE. BOP. (RRP RTDR BI, ASE RAR RR, ZOE REE. EPR. ET ES) Vis RAWAL EBL, ADIL AR BAAN RAE SPRL AL EMR BE HUORA, ARAL BM, HLL. AECOPD 84 4F IPPV YT RY, ATURE EME. EDT ER AF SURGE AURA. Sh EBSD. EMPTOR RL EACHARTS RESO MAIER (2007) 171 HE. NUP ETOCS oh BRAS ARE ULF AR EAR SOP a SU BTL a OD EIN EE PA OR LA aU) BR LE ICU Tay), ELSE EJs AT fa Be He RP AS 5 PT Be Dt SB TG BE BUREN TIM AUS COPD RE TT + PRK SHE EH RA EOE BAB WAME. ALLER Sd EEE AGRE. GUNES BRS CERT s AAT CE MIF. BT te Ba IK CE HIF AS (percutaneous dilational tracheosto- my)(5), EBM 10, HF AECOPD RA CAALLMAHRBOLERE, (DA) (|) BARKER SSR 1. CBE aE FEW, NT PALE RE, GPS AB ON Sie. 1h ‘hs aR ae > Hl HPT] HE Se CP i ATA HS CB. FABER IVLSS FTE BS 9H BA a o TARA EM RAKE, TR FAR FAA a CE, REAR AY ENP, AA A AE FT ER AK Sh NADL HE. HAN A Ps CA/O), TAR HE HA CSIMV) AURA XS CPSV) th BT A — 2 Ae A (PAV) %. Jer SIMV+PSV Fl PSV BARS WRRAM, AL. PSV FMEA fh Ae. ALR ALR INE Be SH ee A HAL HE: ae. RISE. Ab aL RI] ae eT FA. a AER BE AY SIM ISN, RAAT Rito A EMRE. PAV SEF RRRUTBE. Ska S— ERO. 2. HAS RAT DPH All PEEP§ ff) 4¢ (ESP BOY Ik eS A HE BE PE, ER SEAN Ae FT GCOS hal 9H Ue EF ak SV EE Ay RRP AACHIY PEEPe, PERM CRRA NRE. CHALE. CD WIA (Vr) RAGE (Paw); BRACE) 6~ 8ml/ke Bll FY, BREE AA BR 30cmH,0 Al CR) ii EAR REE 35 ~40emH,0, Dil, DPH AYE —3b AU Bi A; USERRA — eA PRUESEAC IES CHE, {8 PaCO, (APE MT PRA BILE IOE, WHE PaCO, F Bees Be it FSCS OP ELBE (2) EUS (OD: ESRI VRE A, EE HL SHE BY BH DPH I. —fBE 10~15 Yc / SPAT,172 WeRessisrs Be a aE (3) WARE flow), —ARGR FREER ADEE (40~60L/min), {RIF He CE) <1? 2, DURES, [alta AECOPD AB a Bedi 093 Ute BEATE MIRED), TERR AUAZEHAO WRF aS AO RE SE ALE RK. MT COPD RF, aa De Sy FC ft TP ae FE AE ET PR SBE FS Wi > IC ZIRE ak AER PaCO, SHAY (4) Shiite PEEP (PEEPe) : SiH 47K°F #8 PEEPe BT LA BiR{R AECOPD RSMAS SHEA, MMB RRA Setar. ERR. oe SA BLEREES 7-7), PEASE at PEEPe — AR Lt PEEP ft) 80%. 7 zh, DPA” ARATE BAITS Cexpiration hold) jill Htifi2% PEE- Pi, CLAY OR AUR PPr MEAT BLE: TERE REF SER OP FP a8 SH) PEEPe, [rl np WsaP AAR, PLAS S| te 3F A AE OR ab Ft itt AUS PEEPe AO”, (5) WRI CFiO2): EARLE, AECOPD Fe Se {RF AS SR ERE AY LAPEER SEAS OLS A a BE BEG KP OA EER HARI. HS FEE RHE CD FP ACHE. AUNT, RSE. OU. BAe ARG ER 1, MARA ERITH AECOPD BA APIA HA, RA. (DAR) ABER 12: RRA) ERIM AECOPD RHF ARAMA MAE FRI, Hae ik Sea, (Da) RHEL IZ: HRA ERT AECOPD BA ABT SRK WU PEEP, (D#&) AEM 14: $427 4] EBA AECOPD & # Si % PaCO, 4 Madik, (EM) CPG) EN 1. OP AIF 0 HE CD AGHA: AP SMa ALOR til HE (<< 35~40emH,0) APE HE (<30emH,0), DGS UR GIRL. SRM HE ANSE EE Be GH AM SHAH BA JIN PEEP i (8206), TF Es EE A EB FH Al PEEP 6 82 086), Ja AY LAT BLWTPE Ginspiration hold) Wt. RF AECOPD BA, ZEAL AUB Ah OR. Ho A AA GR) DPH ROTA Ae. EEF TD I HR ES Da, DP Dn a eB WES RA.HERE BtS DES SAV AIS (2007) 173 (2) PEEPi; PEEP i (ty ats38 5 A Ci BA 2 A ABAE LAL i J BOSE PS a] DP AS HAT ST A RR AE LA Be OR FEE Ween AFSL HI BF PEEP #24 AY FT REE: CF AL I a OF RAEN: ORF ERRARCAARITER Chl “SME” He) LAB THA AYALA ASI; OME DLO Fe SCI AP A ES 5 2A SURE AR ADE GTP. Fra MERE MIN Bt PEEPI. BT ROR ANE CARE BT #& (expiration hold) #lgeey SBE RE. (3) AUEBAAT Raw): “QiK BALA 95 4: FEE LB UR A A DURWE. ORE EE. STE SE SRE CAE FE AT HE GRATE, Remy Raw ASRS Be >, Ae EP Wh FN PRT A Ae A APR SEED SK MIST ES HT 2. SUA SEH AO Mean IRATE SUR SCA PER, LHL APT. RA CO, ERE CSR. CEE pH Al PaCO. ASFA. aS PaCO, FReat ‘Beit SBA Pk PHA Be: MAEM 15, 4A ELH) AECOPD & HB ae at UE, PEEPi 40% 85h #6 85 EIN, CE 8) CH) Ff SLE Bee 1. UE Ea ES LR 2 60 $B TEP Cpulmonary interstitial emphysema, PIE). BE Ui. SRR ANCHE, EEA PIE JES AR AY SI Ze, EI DRA 22 SUA — PBS} A ALE PIE, AAU a Be BAC a eH AG, IER A PLE SUE est JE In A ERE URGE RAE PRE LEH AA RESP, iS RCRA a ATO RA, chee DPH AAAS OE CUA. BID, AECOPD (825 20455 (65 (89 DAUD BASE J. Be PE RE A a PARE EPR Hl i A BR BEE, TLR Shas Fe IE FY RE BR J» COPD Re AACR Oi AB ET BE 29K), 2. WEAF ENA CVAP) COPD F224: VAP H—SUAR ER AR, Ti Bute 47 PPV, SAUTE HI RRC, Bee VAP. HA VAP fe EE ICU at TREE, FETA BS, UGB VAP Ay eee et AECOPD A HUA174 BROTHA FRET AA AWRY. VAP BBM ERI. SO UAT, EM. TTR Pee svi. ATR CAME), AFCO ALGO 3. LTT AECOPD 282% 145 5 A BURT BR 5 BBA HG HE AE LAT SH, LAR ASU. 4h PEEPe, Wat. WEE ABIES. JMURPNA EAE IN DPH, DET IMR. RA OUSE ACHE, ROMMEL, HLURB MER. tH SLE ERR BES. ULAR MII «ECE ERAIE AR A AE ASG PL 28 ER BATRA AFF AEE CA) Ai CUE FR OTS 4 LLL BAREIS, PDA UETT HDL: DS ELIE EIR AO 2A BURA], BOMMLIY TERRA E. MAE ANA) BT FT (AE B99 EB BR I J LA Se OSHS. TEARA: QAEFREAARKA: OHARAAWIER WF, PaO,/FiO,>250mmHg, PEEP-<5~8cmH:0, pH>7.35, PaCO: ik 2% WEVA: Qian ee | FEET LGM. ALA He TAIT BRA BARR. MRR AL LPR ARG TT MBE IAB SIM TRC SF IED MEA AER, LER BEM, AA ee aii SIMV+PSV Ail PSV Mist, 7632 A SIMV+-PSV AESCULUS. BT ZEHR RE 4K SIMV WHR. YUMA 2~4 UK / a E P i. PR Stok OF, FLFR AE SEI EE EF BEL A FR KR (S~7emH.0). BRE A ~ 6 “I TUBAL. Yoshi A PSV BSC HRCULINS He Ja SC BRAK AF RS RIS AL I. GHC ADL Ay OAL EK. SIMV BY E28 In RCOL A BE a). AN ee zs FA HL, 4 EMPWRIRH (spontaneous breathing trial. SBT) S255 F4MHLAN IT HA—. {AFM} SBT AI AECOPD HA. HKU. Ze BORG 48 INA EE. Atk, SBT Lele AECOPD it PHM ES. 35%~67% BA COPD BR FF CEILI RE, TE 59.2% FPL AC Ta] J SPSL. eR! © 8 ACE AB COL PRE 9 SEB DF OR OE A TP it ZA APOE. BEL ALL ELF BE. AR a SHR PEEPi #106 028 EO, IAT PEAR Oy REAR! A PURPA BE a. ATLL. Mt aACOLPR ERY COPD A. AEE TPE RI Ae FAY AEMTSER 8 EMPORIO TRY, EME BLUR RPE; ORSEERA REE SSOOUREUER (2007) 175, TER FRAG: PARLE TA HACK HD. TRIP VL AS AS HA ES HER AL ROR EE, Owe DWF WL i iy: UREA PEEP #1 it BALI BUD DPH AGAR, HRA TAME, QUE RR: ONTA OY REWEH, HOLT Sh ARE: OUR Se. HEA RL fea. WEE, BIA SMES KE NPPV TSR, ABR ee NPPV 9973, PLA SEP LR, 4a PPV ANGE ICU fT TE, BE ATR BG PER BLE. FEMI PART RIO HT PE AE IBS PSE ML IE AS ER AE ERE SE. PERE WORE AY. ATLA RAE AP OR AB LER, FEB SB OER AK I BACHE BFL Sey ALY DY ACE. REE as Ae AE AUPE RAS HOR A. ERD ERE. SAE 2 DELL. CAB IE ROR A Me POPE a iH SUBSE OE PEEL. gS tn TE EA BS eS a SN BATHE ABEL 16: AECOPD & AGU & HAR 3] ALP RFE AEA] Apt), (EB) RELI: H AECOPD SH REEAL FREAD ES PRA Hid A ft, (ER) RAED IS, & ARCOP RARE. Mort sheen mesTies. (EW) WW. AA ERA AECOPD & 4M HP A 8 HL NPPV HEBMOLAI TIA. ETRE IPPV AEP RR TEAR SSE BLL EA A SEER CLE ZT RS IPPV, JBRAT UE, Se ZiAT NPPV, EIPSh Ae ROT ESE RIG TT 1 HT Sh ae BE AECOPD AE NORA DAS. 9, TPPV ACE TCU pip TB). AER Bie PA ae, HRA HO), (—) Feet AECOPD BAHL PE EG PR OMEL 1. 4 AEE SEAS Te, LDA AF RE SEL 30% WY Sk PEE OR UAB A ET PPV 5p fi 155 Ba 9 i J RE EL, (weaning), MAGYAR BLL (withdraw), ize AECOPD 47 IPPV £4. ARR EEA A Ee Bd BE HIS 35% ~ 67 0°), RE IPPV INSTA] eH RE SRA, NU. FRR. 1 TRR ABR ATAAEAS 4. ATA A SE TT. SRL BP hes Ta176 emer Bake PE TTIR. MPMI. EMPL NA CVAP), (omit RZ $8. LB LIRT IAD SE Ke AFR PREC OTT VAP 55 SE BE Bo SI I CHAP) #8) 2~10 4%, BFA ARETE VAP RAE PHC, AAG HEME HALAS (artificial airway-associated pneumonia)”, 2 ECE ORT CR OOH FS aH PT] ET WUD ALAR IF HE. ROBE NPPV HAL cee. 2. SEUEIE EME. BEE NPPV 45 IPPV YES BIE PR A AT. aE AURA GS, 45 IPPV pate, NPPV [alee 8] D1 st BEF RFE A BEA RO, ALE. AT DELP AA PEASY Ws | AAS JRA EA GLEE. Bib. PIER ARSE) APR AEH AE. HP NPPV RGA SEMPRE IAT. HEAT GHANA IE ER A RR AE — it» RI NPPV 4 BSL FER ER RT FE. HOLS 48 Int PN ATE AR HE 56 ~ 15.4 Zi, TR EF BR AE ICU CADRE Fn] BY GREASE AY AR ME Be Be EB NII, RL, MIS He HOLS EAD ET ARCOPD 2 oR Ja 22 BG a Bi NPPV VA 6 (4 SE. BT FCT EO EEE Se A NPPV *F Fite ENP OR NAA AY AECOPD, FE ib SEE EE EO Dt TY 1S 2st A EAL 97D fo FA NPV AAR A. ECU i 9 PERE. MESA SP BT Abas NPP V B33 BP TE 9 5 PES CE Ea AR I IO A BE HOS SANS PESACUL fe GF De Be 3 DE F-GE] NPPV. OE To Sb WALAIT (25 %vsl4% 0), PAG, PM RABE SEL ET ET AAR AG. AG RUINED NPPV fH SRGE 5 AS DS Pp A 2 ¥ NPPV Fil. (=) FERRIC 0 TE ASS A CL AS SH MSHS ite NPPV $i BIL CRE ZE FUE. IPPV 49 NPPV 11% SCAG. NPPV SUERTE. JE ARAL NPPV 48 COL 84975 PP 6 i TB FA NPPV A AS tt. FA. AF NPPV (93 CSC OP AT BR. MEP REM MD BE 1 ET ONE Se Rp KE a BA A A. Ale. fe BRAT RR NPPV Ag HL A RCT 09), 5 Be a AIG LA ES HEE. CE I PDE AF 9 — OE 9S pO, BOR AERA PIR ANGE 85 3, GU 1 EAE IRE AL, IFT AVP ZS — UF ER: Pt BB AP. RPE. PHARSRM ABE ES CR TSR (2007) 177 BL, PRLEMELA 24 TE AO AREAL SCR / TAB AG ROR AT AR HG RRR HH ‘Sch, NPPV SE sSHOLAY A + 328 AE IE oH HEA IPPV 4625 NPPV #8) bd AT COPD 2 ¢£)n i ESE oy OE BRIE |Z, AECOPD A HE WA ALAA SOR BOF a UGE Ba» TE IPPV 5~7 KBP RA EA ARR & ATS BEET WK LA LD. BBE. HERE. PRUE BE. SMART ORAR. X 2 Ae bE RB TGR NB RRS BEST Bee “UAB (pulmonary infection control win- dow, PIC window)”, PIC gif 22 ¢ EFA 7.280 Ye #8 3 9 Ii FASE Ba tH SEF HE BY ~BEWIA], HBL PIC af a eR ATE. ON LAT A HU] HE IF VAP. HSU PIC By bet A 78 RE S| Bic RAN A TP LE SY SB HEROES. CS IPPV. 4k NPPV. BEAT E—JE Se ARE WLR, BEE HE. MAPA VAP, BRAC". ESN PR RIE oe IPPV GULL T FPL IE, AL MCE AT NPPV FEDIHRCEL. SLIT AS SB BH) COPD 18 ADR LIER » TAR AH LA PIC BALE eB COPD APE ILO MLA Ha PBR HEU 1a SPA BEM SB I OR I FE AE. AEE Ee EBC aA] NPPV. Putt. SLE ERY NPPV REPRE AAP aR HEUER SIE, MSC NPPV a RCD LAS A — Ee . MAE RLY: AA) ERTL AECOPD BA PMREOHARFR, (BA) MEL 20, tT RAUB a RK AGA eSB HH AECOPD & 4, TVA SR RAS H] GE HA OAH AAT. (BM) CHEE SR Ee AE do AS OE 48 (2007) aS th A a me i CBee 8 Ba SHS E mR MAA H Mt MBG A RT MR RRL Bem 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD)2005. www. goldcopd. com. 2. Tarkington PM, Elliott MW. Rationale for the use of non-invasive ventilation in chronic ven-178 wResiem fi ETH Mt tilatory failure. Thorax, 2000, 55: 17-423. 3. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med, 2001, 163: 283-291. 4, RossiA, Polese G, Brandi G, et al. Intrinsic positive end expiratory pressure (PEEP) « Intensive Care Med, 1995, 21; 522-536. 5 FLAMERS, ER. BAUR, SB. OREO TE He U8 HE MELE I Ph ma. HAR PY ALN. 2001, 40, 385-389. 6. Ninane V, Yernault JC, Troyer AD, et al. Intrinsic PEEP in patients with chronic ob- structive pulmonary disease; role of expiratory muscles. Am Rey Respir Dis. 1993, 148, 1037-1042. 7. Collaborative Research Group of Noninvasive Mechanical Ventilation for Chronic Ob- structive Pulmonary Disease. Early use of non-invasive positive pressure ventilation for acute exacerbations of chronic obstructive pulmonary diseas controlled trial. Chin Med J, 2005, 118 (24); 2034-2040. 8, Elliott MW. Non-invasive ventilation for acute respiratory disease. British Medical Bul- letin, 2004, 72; 83-89. 9. WRT. FUR. Fi GPE AAO NL AaB AE. ee ER Ae; 2002, 25 136-137. : a multicentre randomized 10. Nava, Ambrosino N, Clini E, et al. Noninvasive mechanical ventilation in the wea ning of patients with respiratory failure due to chronic obstructive pulmonary disease; a randomized, controlled trial. Ann Intern Med, 1998, 128 (9) 721-728. 11. Ferrer M, Esquinas A, Arancibia F, et al. Noninvasive ventilation during persistent weaning failure; a randomized controlled trial. Am J Respir Crit Care Med, 2003, 168 (1); 70-76. 12. AA AVY POLES OPE. “UR BT” YU TH OS FR REST AE EB TB OP EN OH} TE LH 3 PEL RAPA, 2006, 29 (1), 14-18. 13. ABHWGR. HUH. BE, BALANCE OL ATT RE EE CE SEP PORT. PHABREAAE, 2005, 14, 21-25. 14. British Thoracic Society Standards of Care Committee. Non-invasive ventilation in a- cute respiratory failure. Thorax, 2002, 57; 192-211. 15. Keenan, SP, Sinuff T, Cook DJ, et al. Chronic Obstructive Pulmonary Disease Ben- efit from Noninvasive Positive-Pressure Ventilation? A Systematic Review of the Lit- erature. Ann Intern Med, 2003, 138; 861-870. . 16. Bott J, Carroll MP, Conway JH, et al. Randomized controlled trial of nasal ventila~ tion in acute respiratory failure due to chronic obstructive airway disease. Lancet, 1993, 341; 1555-1997.{CHER SCENE BIE DRS OER (2007) 179 in 18. 19. 20. 21. 22. 23. 24. 26. 27. 28, 29, Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med, 1995, 151; 1799-1806. Brochard L, Mancebo J, Wysocki M, ct al. Noninvasive ventilation for acute exacer- bations of chronic obstructive pulmonary disease. N Engl J Med, 1995, 333; 817-822. Celikel T. Sungur M, Ceyhan B, et al. Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure. Chest, 1998, 14 (6), 1636-1642. Avdeev SN, Tretiakov AV, Grigor’iants RA, et al. Study of the use of noninvasive ventilation of the lungs in acute respiratory insufficiency due exacerbation of chronic obstructive pulmonary disease. Anesteziol Reanimatol, 1998, 3; 45-51. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exac- erbations of chronic obstructive pulmonary disease on general respiratory wards: = multicentre randomized controlled trial. Lancet, 2000, 355; 1931-1935. Martin TJ, Hovis JD, Costantino JP, et al. A Randomized, Prospective Evaluation of Noninvasive Ventilation for Acute Respiratory Failure. ‘Am J Respir Crit Care Med, 2000, 161; 807-813. Thys F, Roeseler J, Reynaert My et al. Noninvasive ventilation for acute respiratory failure: @ prospective randomized placebo-controlled trial. Eur Respir J, 2002, 20: 545- Delcastillo D, Barrot E, Laserna E, et al. Noninvasive positive pressure ventilation for acute respiratory failure in chronic obstructive pulmonary disease in a general re~ spiratory ward. Med Clin (Bare), 2003, 120 (17): 647-651. Keenan SP, Kernerman PD, Cook DJ, et al. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta a~ nalysis. Crit Care Med, 1997, 25 (10): 1685-1692. Peter JV, Moran JL, Phillips-Hughes J, et al. Noninvasive ventilation in acute re~ spiratory failure-a meta-analysis update. Crit Care Med, 2002, 30 (3), 555-562. Lightowler JV, Wedzicha JA, Elliott MW, et al. Nor tilation to treat respiratory failure resulting from exacerbations of chronic obstructive vasive positive pressure ven- pulmonary disease: Cochrane systematic review and meta-analysis, BMJ. 2003, 326: 185-189. Hill NS. Noninvasive Ventilation for Chronic Obstructive Pulmonary Disease. Respir Care, 2004, 49 (1): 72-87. Bardi G, Pierotello R, Desideri M, et al. Nasal ventilation in COPD exacerbations; early and late results of a prospective, controlled study. Eur Respir J, 2000, 15; 98-104.180 mmo ERY 30. 31. 32. 33. 34, 35. 36. 37. 38. 39. 40. 4l. 42, 43, 44. 45. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med, 2001, 163: 540-577. Diaz O, Begin P, Torrealba B, et al. Effects of noninvasive ventilation on lung hy- perinflation in stable hypercapnic COPD. Eur Respir J. 2002, 20; 1490-1498. PMG, BUR PACH, SE. TENS FH NE FG FE i PO HT BORG. PARA, 2004, 24: 90-91. SES TKI, DIRE, SS. AOL SAUL AM RT MILE TT RLF ee BELT AR FE. ‘PPRGRUEAE. 2006, 26: 64- Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medi- cal treatment in the ward; a randomized trial. Intensive Care Med, 2002, 28 (12); 1701-1707. . Squadrone E, Frigerio P, Fogliati C. Noninvasive vs invasive ventilation in COPD pa- tients with severe acute respiratory failure deemed to require ventilatory assis- tance. Intensive Care Med, 2004, 30; 1303-1310. FRA. PER TRL. AE. FEAT AS ce EB a A BLDG. . “ATA RBEF, 2000, 20, 511-513. Confalonieri M, Garuti G, Cattaruza MS. A chart of failure risk for NIV in patients with COPD exacerbation. Eur Respir J, 2005, 25: 1130-1131. Scala R, Naldi M, Archinucci I, et al. Noninve ive positive pressure ventilation in patients with acute exacerbations of COPD and varying levels of consciousnes 2005, 128, 1657-1686. HIER, I. LARA. SF. UIA RI AT TH a A HE OE PRA . PAR MIMPMLRE. 20038, 26. 381-382. Levy M, Tanios MA, Nelson D, et al. Outcomes of patients with do-not-intubate or Care Med, 2004, 32 (10); 2002-2007. Guilherme S, Neila A, Kacmarek RM. Noninvasive positive pressure ventilation re~ Chest, ders treated with noninvasive ventilation. verses acute respiratory failure in select “do-not-intubate” patients. Critical Care Med- icine, 2005, 33 (9): 1976-1982. Mehta S, McCool FD, Hill NS. Leak compensation in positive pressure ventilators; a lung model study. Eur Respir J, 2001, 17: 259-267. Stell IM, Paul G, Lee KC, et al. Noniny: structive pulmonary disease. A test lung comparison. Am J Respir Crit Care Med, 2001, 164; 2092-2097. Elliot MW. The interface: Crucial for successful noninvasive ventilation. Euro Resp J, 2004, 23; 7-8. Schettino GPP, Tucci MR, Sousa E. Mask mechanics and leaks dynamics during non ive ventilator triggering in chronic ob-REMI A RSC BRE (2007) 181 4 47. 48. 57. 58. 60. = TE Bee UE HE St Sob PRP MR AE BD ICU S24. FOOTE AE UPR PEL, |. Holzapfel L, Chevret S, Madinier invasive pressure support ventilation: a bench study. Intensive Care Med, 2001, 27: 1887-1889. Ferguson GT, Gilmartin M. CO; rebreathing during BiPAP ventilatory assistance. Am J Respir Crit Care Med, 1995, 151 (4); 1126- 1135. BA. DR, kh. F. AUER NAAM AK SR OA. REA BEANTP RZ a 2005, 28 (12); 875-876. PRA. TR AGAR, (TEE. SE. SUT CRC A I A B . ABER AUF MRK. 2000, 23 (12), 734-736. BL. PHAR AMER AE, 2002, 25 (3), 130-134. RAE. TASC EIT UFR BEM . HABER AEZRA, 2004, 84, 435-437. . De Keulenaer BL, De Backer A, Schepens DR, et al. Abdominal compartment syn- drome related to noninvasive ventilation. Inten Care Med, 2003, 29 (7); 1172-1181. Hill NS. Complications of noninvasive positive pressure ventilation. Respir Care, 1997, 42, 432-442, BBR. KAS, BE. SE. REFS CO) EP BE LR AT AY BLAU . PRLS UReBE#, 2001, 21. 360. + et al. Influence of long-term oro- or nasotra~ cheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a pro- spective, randomized, clinical trial. Crit Care Med, 1993, 21; 1132-1138. . Salord F, Gaussorgues P, Marti-Flich J, et al. Nosocomial maxillary sinusitis during mechanical ventilation; a prospective comparison of orotracheal versus the nasotrache- 390-393. al route for intubation. Intensive Care Med, 1990, 16: » Michelson A, Kamp HD, Schuster B. Sinusitis in long-term intubated, intensive care patients; nasal versus oral intubation. Anaesthesist, 1991, 40: 100-104. Bach A, Boehrer H, Schmidt H, et al. Nosocomial sinusiti tients. Nasotracheal versus orotracheal intubation. Anaesthesia, 1992, 47; 335-339. Rouby JJ, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of noso- comial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med, 1994, 150: 776-783. in ventilated pa~ . Rumbak MJ, Newton M, Truncale T, et al. A prospective. randomized, study comparing early percutaneous dilational tracheotomy to prolonged translaryngeal intu- bation (delayed tracheotomy) in critically ill medical patients. Crit Care Med, 2004, 32; 1689-1694. Griffiths J, Barber VS, Morgan L, et al. Systematic review and meta-analysis of studies of the timing of tracheostomy in adult patients undergoing artificial ventila~ tion, BMJ, 2005, 330: 1243.182 Bsmesiem Bi EFM él. 62. 63. 64. 66. 67. 68. 69. 70. mL 12. 73. 74. 1. Arabi Y, Haddad S, Shirawi N, et al. Early tracheostomy in intensive care trauma patients improves resource utilization: a cohort study and literature review. Crit are, 2004, 8 R347-352. Friedman Y, Fildes J, Mizock B, et al. Comparison of percutaneous and surgical tra~ cheostomies. Chest, 1996, 110; 480-485. Gysin C, Dulguerov P, Guyot JP, et al. Percutaneous versus surgical tracheostomy: ‘A double-blind randomized trial. Ann Surg, 1999, 230; 704-714. Tokies L, Hedenstierna G, Svensson L, et al. V/Q distribution and correlation to atelectasis in anesthetized paralyzed humans. J Appl Physiol, 1996, 81: 1822-1833. . Downs JB, Klein EF, Desautels D. Intermittent mandatory ventilation: a new ap- proach to weaning patients from mechanical ventilations. Chest, 1973, 64: 331-33 Ob, EAR, BOUIEE, SP. HCPA CURR AT ET hee AGP RAS. 2000, 4; 228-231. Tuxen D, Lane $. The effects of ventilatory pattern on hyperinflation, airway pres- sures, and circulation in mechanical ventilation in patients with airflow obstruc- tion. Am Rev Respir Dis, 1987, 136: 872-879. Del Rosario N, Sassoon CS, Chetty KG, et al. Breathing pattern during acute respir- 160-2565. Bonmarchand G, Chevron V, Chopin C, et al. Increased initial flow rate reduces in- atory failure and recovery. Eur Respir J, 1997, 10 (11) spiratory work f breathing during pressure support ventilation in patients with exacer- bation of chronic obstructive pulmonary disease. Intensive Care Med, 1996, 22 (11): 1147-1154. Connors AF Jr, McCaffree DR, Gray BA. Effect of inspiratory flow rate on gas ex- change during mechanical ventilation. Am Rev Respir Dis, 1981, 124 (5); 537-543. Yang SC, Yang SP. Effects of inspiratory flow waveforms on lung mechanics, gas ex- change, and respiratory metabolism in COPD patients during mechanical ventilation. Chest, 2002, 122 (6); 2096-2104. Smith TC, Marini JJ. Impact of PEEP on lung mechanics and work of breathing in se- vere airflow obstruction. J Appl Physiol, 1988, 65 (4); 1488-1499. Petrof BJ, Legare M, Goldberg P, et al. Continuous positive airway pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe chronic obstructive pulmonary disease. Am Rev Respir Dis, 1990, 141 (2): 281-289. Guerin C, MilicEmili J, Fournier G. Effect of PEEP on work of breathing in mechan- ically ventilated COPD patients. Intensive Care Med, 2000, 26 (9); 1167-1169. Georgopoulos D, Giannouli E, Patakas D. Effects of extrinsic positive end-expiratory pressure on mechanically ventilated patients with chronic obstructive pulmonary dis-76. 79. 80. 8. 84, 85. 86. 87. 88. SHERMAN SS MEIER (2007) 183 case and dynamic hyperinflation. Intensive Care Med, 1993, 19 (4); 197-203. Ranieri VM, Giuliani R, Cinnella G, et al. Physiologic effects of positive end-expira- tory pressure in patients with chronic obstructive pulmonary disease during acute ven- tilatory failure and controlled mechanical ventilation. Am Rev Respir Dis, 1993, 147 (D: 5-13, FER WERE ROR AR PEE AE DED. ESA AE MARAE. 2005, 28 (2): 75-76, . Anzueto A, Frutos-Vivar F, Esteban A, et al. Incidence, risk factors and outcome of barotrauma in mechanically ventilated patients. Intensive Care Med, 2004, 30 (4): 612-619. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-as- sociated pneumonia in critically ill patients. Ann Intern Med, 1999, 130 (12): 1027- 1028. Heyland DK, Cook DJ, Griffith L, et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Tri- als Group. Am J Respir Crit Care Med, 1999, 159: 1249-1256. Canadian Critical Care Trials Group, Canadian Critical Care Society. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med, 2004, 141 (4); 305-313. . Brochard L, Rauss A, Benito S, et al. Comparison of three methods of gradual with- drawal from ventilatory support during weaning from mechanical ventilation. Am J Re~ spir Crit Care Med, 1994, 150 (4); 896-903. Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning pa tients from mechanicalventilation. Spanish Lung Failure Collaborative Group. N Engl J Med, 1995, 332 (6); 345-350. Esteban A, Alia I, Tobin MJ, et al. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Col- laborative Group. Am J Respir Crit Care Med, 1999, 159 (2); 512-518. Esteban A, Alia I, Gordo F, et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collabo- rative Group. Am J Respir Crit Care Med, 1997, 156; 459-465. Vallverdu I, Calaf N, Subirana M, et al. Clinical characteris ies) respiratory func- tional parameters, and outcome of a two-hour T-piece trial in patients weaning from mechanical ventilation, Am J Respir Crit Care Med, 1998, 158 (6); 1855-1862. Lemaire F. Difficult weaning. Intensive Care Med, 1993, 19; 5692-873. Goldstone J, Moxham J. Assisted ventilation. 4. Weaning from mechanical ventilation. Thorax, 1991, 46, 56-62184 ners Ti aah 89. 90, gl. 92. 93. 94. 96. 97. 98. 99. 100. 101. eban A, Alia I, Ibanez J, et al. Modes of mechanical ventilation and weaning. A national survey of Spanish hospitals. The Spanish Lung Failure Collaborative Group. Chest, 1994, 106; 1188-1193, Purro A, Appendini I, De Gaetano A, et al. Physiologic determinants of ventilator dependence in longterm mechanically ventilated patients. Am J Respir Crit Care Med, 2000, 161; 1115-1123. Jubran A, Tobin MJ. Pathophysiologic basis of acute respiratory distres in patients who fail a trial of weaning from mechanical ventilation. Am J Respir Crit Care Med. 1997, 155: 906-915. Larca Ly Greenbaum DM. Effectiveness of intensive nutritional regimes in patients Crit Care Med, 1982, 10 (5): who fail to wean from mechanical ventilation. 297-300. Lemaire F, Teboul JL, Cinotti L, et al. Acute left ventricular dysfunction during un- successful weaning from mechanical ventilation. Anesthesiology, 1988, 69 (2): 1-173. Girault C, Breton L, Richard JC, et al. Mechanical effects of airway humidification devices in difficult to wean patients. Crit care Med, 2003, 31; 1306-1311. Girault C, Daudenthun I, Chevron V, et al. Noninvasive ventilation as a systematic extubation and weaning technique in acute-on-chronic respiratory failure: a prospec tive, randomized controlled study. Am J Respir Crit Care Med, 1999, 160 (1): 86-92. Ele. PANGS. BEAR, RE. AS FEL AES IT 1 PE EE ETB POSSI TSE . AES AINPRA GE, 2000, 23; 389-390. Kollef MH. The prevention of ventilator associated pneumonia. N Eng J Med, 1999, 340; 627-634. Kollef MH. Avoidance of tracheal intubation as a strategy to prevent ventilator-associ- 2 55: Kramer B, Ventilator-associated pneumonia in critical ill patients. Ann Int Med, 1999, 130; 1027-1028, Vitacca M, Ambrosino N, Clini E, et al. Physiological response to pressure support ated pneumonia. Intensive Care Meds 1999, ventilation delivered before and after extubation in patients not capable of totally spontaneous autonomous breathing. Am J Respir Crit Care Med, 2001, 164 (4): 638-641. A Collective Task Force Facilitated by the American College of Chest Physicians, the Merican Association for Respiratory Care, and the American College of Critical Care Medicine. Evidence-Based Guidelines for Weaning and Discontinuing Ventilatory Sup= port. Respir Care, 2002, 47 (1); 69-90.EEE BENS SCA SA (2007) 185 102. 103. 104. 105. Epstein SK, Ciubotaru RL, Wong JB. Effect of failed extubation on the outcome of mechanical ventilation. Chest, 1997, 112 (1); 186-192. Torres A, Gatell JM, Aznar E, et al. Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Am J Respir Crit Care Med, 1995, 152 (1): 137-141. Ferrer M, Valencia M, Nicolas JM, et al. Early noninvasive ventilation averts extu- bation failure in patients at risk: a randomized trial. Am J Respir Crit Care Med, 2006, 173 (2); 164-170. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med, 2004, 350 (24); 2452-2460.SERS RRIRERRCMS jOTs 43H (2007) PREPARED ICU RS EEA HE RIE Cinvasive fungal infections, IFI) MRA #, HIP IEMOY PICU LARC WRE AZ —. HAT, ASA eee AE IF] RHEE LA invasive fungal disease, IFD), ShM AT FIC. ARE BE TEER IFLA. RU, PAR HE Be SMU RR, HAGUE AP LA SMSC AUB. Hale Ta NERO CITA ITs SES. AE SS ERP ICU AE A RR SE BRLE. —, ICU B# IFLA aT 1. ICU AR 2 IPT AY Sem PERL ASHLEE ICU 2B 2h IFT tea AN WTP EG. 2G BR BEATE HERBIE 86~ 15%. DPR TE AYRE EERE Be ALL HAE EY ARE TPT LAR. SPS 91. ASO, fl, OREM CRS SC A MERA 4, RN. BT OL PAR HS AY BEE 20% ~ 40%. th ATS ABBE Be Ae A BRS By AEE 90%. RAPA DATTA RK RS AA. ERA TAT onlay tht, 4A IPT by Ae SE BH OE FPS, 2. ICU Aba IF] BER ICU AR 2 IP] AR I EL RA AH. CU AR AE TFT TUR BA SE BP AR Re AC 40%~60%). (AURA RE CCHS. AVHRR SRA. WER SRS) RL be BCE a TS I, BR TEER BOR AY BA OS eM Ft, TAT IFT fH) 5.9%~12%. hh 5 FFE FPN BAB FL GRE RL RSE, BCH PE Eas PR Aco TS ak 7 Sc 6 WL Je Hn is. a eB ae AR aE Bo Fish BEA HAAS IA. RHO A a Bee wa AAR I 5 I 9 ST FBS 186SEPSRAKABOMCM SITS (2007) 187 3. ICU Bhat IF] Bae ICU RF IFT ARERR. MLK TA BE, MRE. ABRE VE ORR SE EIA 30% ~ 60% mi AER RL ML HE AR IP IE SL PEGS 40% ~75% , HEHE SBR AUS STR A RH FRAG HME FRG ICU #8 5 2 HE HB Re ee RE, ES, ERED ABI “tl OE TN 8 RA 4. ICU ah IFT AREER ZL ICU HH, IF] BRT BY ARE Fee ee FEMME ESE SEEM HATE Oh, BES A MU BE PE EA FUCA HY HAE AS CG aA Et RIT GA FLAY ERIM / SHE ERR WAX. AG SEAW ALE OH A ICU 8 eI OP i PE PEAUDRIR. TCU AR CEE TTA & Be Bes A dP EE TE FA, BEF A OI RST AEE 8 HELE Gb -ge eID AAU He Se TT A AR PR BL BBP OB TA FERRER BAAR 5 LK. ICU 4 IFIeEAR ER GH: OICU RATER AMA: ORA PEM ATF IAs OMA TRAMs OM AIPA. Bete BEAR CENTS. NEE SRR; OAS TCR 5 ee N IT A ZEM REAT IZ As ORF AMA ITs OM eT / BOT. ATV Bee BUR a ewe THAEIR Fs @BEA ICU BIR PAB. BERORE BRE FRY la] SE ICU Amp fal EAS =. FILS MRR 5) de IF] ARAM) OOS. SEBO SR ABO. RA SEAN, ERABARWRESRALH, CITT RAMEE, WE SBIR REPS BO. TERETE PH BEBO BRIT BURR AETHER. RABUN PER BL SORA SMA, SRT EI HE Se. SHR, HE. RRR, ELI a Ll IPL 1. BORVERUAR QUART HL 28 RESORT. ALA BO ea SRE (BARES) A. ERR. PARRA. PRA. ERK Hi, RACHA, PURER, WTS. EER IEPT AE EEE T. SBGEUBE ES » BROGIRSREE SD, RBBSP RTARTA EERIE Yn BU BH LS FA Be RR] PA188 RBIS BE a Ff. 6 37°C MI PHS 2~3 NE, PT SEE, HEHE BEY SIRF EAPO. SRA EET ART, KETO. (OSA RIDIE a, AA AUR LNA SBR. HAAS AR CE. AS SA WO BABE. QP TRIE EAA 2 OY OU PES TREN SB Re 5 LA RE UHIK. 2. BOR PEW BE ANREP AER. Bw MH RE ANY Ap ae AE Be AS SMR NS. ARE ER ROBT ATE; RIE SE HUF SAVE MET EOS + SRI DLP AE Hl FATE AS A PL PH A. DUMMIES A EHO FE AS SET EE. HOR ARETE HENL. At FU SF Fe EE PCH RE EES PS. WEF 2~Sum Ks, BERT RE. RAMS Jer AT 5 HEA Wi AUR DE HRT SER ACR AE SEB SEAR AST 7H A APA TAI RS A SME DARE TE HAMA, HARE AT WAR Ay Se AB I SEAR RS BED REP SSA. RENT ERASE KE, PRG EE SRY. 3. BOPTERERTA RAR PAI RTE RR ER PA Fie ot LA BO. LE ER, RUBVERR RA EM ATE WAT LAA, AE FEF RSE SERED, JUSTE AIDS SASF 2c BER BR SY BAERS: eR TP, Beh or 8B, ASU TERR ASR A WT EE a GEERT LRT TB MHD, ELS 2~Sum, SGI TL SER. ARR PR AT AGERE TERE AM MO BEE SEI, (BORA SHE. POA LARA PBI. A aA BUN. PRS RAL MAAS, US IE, FL ea AMPA, RRR EAE AT AIDS. PERRI. WRU. ASHES DEAR. HA BASRS. 4. WPCC TEA LAAN 37°C Set FP REREAD ZE 27°C FR DT ARN, RA. ES Se Gy AREAR AE. SRA SUI, RH. ROE, BRE. HF 22 AED BES Pa RS, HEE PR, EK Ze he ORATOR, Jy EL BRMEBEI, DSB ST OT Ae WE PO HN EERIE 5. SURE A ARAB AS RRA. He ABO ERAGER, RE. REBAR, WE ABORT. E BELT Mis AUER ET Oe TT AR. HAR URES. BEATER HH, MERI, HABERS RAE BERO MG SISTA (2007) _ 189 ASMA IRAR . PGi, PYRE PE. SCA) BESS Ae. WE, KABA ERA ZS PE HF RR. TUE A BRUM Wis WG RS ZR 6. RECIFE BE S| RR, BR ER ti [28 (pneumocystis carinii pneumonitis, PCP), E38 WL AIDS 45 MHETH FE KEK RA FS AGES BL, EE EAE ESE LR. oR FIFA SAAT 600 MAILE, mS JR Fe 20 NHR. HOR RHE ERA SAR PASS. EERE LTT NAEP IRAE. SEH HE TEI HARARE EID. PCR SORA EAB ISITE. = .IFI W # X IF] AAR A ARAN. MLR. JERE SA BE ‘EINER. RATE BR AIS RC aS eA PP HEE AA UPL gd? X Fine. FEM CSE) BUR. WORE. ice heer HM Tae w (ER. W. ie Be IF] yo or TRE AR 2 IF] IS BTSY 3 MH: HID. RDI. PLE. IPT AYO —Abin seme Cat) ALR. PRRRIE, Rae. cE HLF SABA. AUREL TY RE (—) tre 1. CRRREL SUR TEAR NTC AS AL 2 RP RE I ATER AIS? TERE, ERR AR. PURE SRE NTE GBR APOE PAT IRS / a PLE ROR ACE OE ETE CR FEUE &) . 2. FAR MLAE LICR IEPA. SEHEDRTS US. TIN AE TEAR a eB TATRA HEARS UAE. . 3. SEPA PE DCR LEY READ BBA RT RIE, 4 GPR CIRBE Sem) °F RE BIE FE AFR TM 1SCFU/ml, ak if BESET > 102 CFU/ml, BLS 4b 08d m3! 3E 9 Tl — BORG a, IPERS} ICI EB Ath Re TT aD. ee FPR RTE EE, ARERR ANE. AT BL SH ER eRe. CD iS ibT RA ER CE) BK, BOAT AT AE RRSABAILAY 1 TSE BI RPE190 mBReTE FRR ea ak 2 USEMREMIE, JEL BP | ACE EAR me DAA 1 ME CHE) AR, Ath 1 SAVED FRASER IE, MF AAT BY REAR CLAY 1 SSE RAM aR 2 SOU i RPE. (OO) ier IFT ASS RR aE 1. fel CGE) VR CL) FES REDY HEIN A AR, RATA RIT 72~96 AL SAE BPA RS TER HBL BSUS HN TE ARE LD REAR: O24 CHR > 65 2), BHAR, NFM, BURA, BE DRAG. PEVESHIE HEN BOG SNARE IR PFDA AN. Ee ti / 01 ha A Be Hl, BERR BARING. OF SAE. LIVES ae CE Rny 4E 27a 2 PELE ABTS HH AT. RIGEDRER ATRL) BRL ABRs AL $B A 2 UARLESE AB ESSER ED . PARE, REAR GA 2 UAE LT. A, RR. MR F. HUGE 5 PAB ARBEIT HE, ii HOH (CD 0. 4 SUBETE MEHR (CCD D0. 5 MARL M. Cl ASM BIEL: 11 / PERF on AB FE CIS ICFU/ml, B/E CI 10°CFU/ml, #8 C= 1O'CFU/mls CCT AZ WMA: O/T RAR Te A FE 0? CFU/ml, WW/ER/PR CCI=10° CFU/ml, 2) TASER: OSA ATEEE: UH > 48 et FL WAS. ARE Ma / AU. STS EA 9 a %, Qe. KATA AL 3 Bae 3 AR OL AE SWAG, SAI. ATER ITS. OMIA FAK: TG 24 it, SET. PEPE IC. EOE, AT ES BUR SETCBAE 2 REA W FAR ACAI T AS, (2) Fete RATA HE AN Ha A COOL eR EAI. TV REE SAL / FP AL PAS ih FES LS FP TET) AA Ym > 38°C M<36C. A PBA ZEAE. 1) FERIA MERE. Ae PRS: OPER RS (<0.5X10°/L) AA 10 ALLE: OLA 60 AA BAL EAL HBR SIF REL 10 Ks QAI 30 AAPL ALIE TEESE Se EMA T BOT (HARE SM 2 AKT 2 FED; OAM ABE eR Cie a A 4PBIEHS 0. Sme/(kg + d) Lh? J]. 2) PEMA A EMEA: OBA PRIA: BUHLBEESRACMBERVG STE (2007) 191 AT OCR IL, BAUER) LRH. BER FARI. PRDY HERE. BRUGES ORS. Qi HA PIER AR: BER, BSnHRGRE (CMV) BR, BAT SET. WRITE 2 TAA AE BERR BERS. OUBAIEA PFIERAR: 4A > 40 YB. CMV BGR. $US HIRE. AUR BLP ERAT a me. QO AES AE AP AEA: RAMBLAS EH. AIF PME RR, CMV AAMAS 3) TALE BPG he ED BION a AY 7 I BE PR ERR — A AR. 2. ti PARP AE CL) SEBERRIE: FA AE ANIM PALS OA RY BOF BE ERE. ‘Ae Re AR BE RE SS «OB RES A DE Bs JAE Chalo sign); AWS ATE Cair-crescent sign); SARK wy HBL SEE. RAPS PRY SOPRA. BOR TSMR NIE PAL STAY BER. BURA BEAR AS, ICU "PABBA HG Re RED) ME AO i BY APT FE (BEAL (2) USORTE: GWA PIB ET SERIE AB ALOR MER, GE, vb 1 HE ROR BE ORME RAL 3 PAY 2 1) PUR ARE: SEIT ER aE REAR RAE I AY AR CORR EE, WOT. MGM. OPO PME, WTAE MARIS SE) 5 POE a) a a AL ORS AR AE SUEY. TE EIR IY AONB TERY 2) WBMES; FL Ag iC t/a RS CER AE CS. BK. AB 5. UURGK. BORE H). TARAS SRA, BUS. BG BPE DRIBLIEES R AE ARCS E 3) WRABE: GPRS, FRSA RI GRRE AR, FI i a NGG SARE, YAS RA RR Rs DRE A Be ee RUE RE CBE WBC>5 4+/HP. ktE>10 4/HP); SFM BRP 7 KOH. AAT EBA AR BR IA EF eR PG AR RE DP RE PRA A) ARES RB: FLA PR AOU AL RETR RARE CUR ESE AE OL . ARE IPR ESE «AAR Reta A Heke SR nt, AC IL Mt aH 5) MLE: AGH BRL SFR OE. oC EE SRE AR REE A BE SALONS TEBE IG ACREDR ITH AY RSA, SRE IG HE RR et PE192 BROT Eee SOR BB. 3. AEE ATR. SAR, HR LER te HAR. HIHERU RSL TINA. HE: OIL. 19 ALK FE PRR RRR TLR PB HE + ume. OME ARAL. LAR GAC IR RANE TE RRL CHER RT OD); OTE AR BERR AO TATUR F . ESSE 2) OPER 98 SEA BP PER DR BR DEE FR ASAIN RAS FE EEE PE CRB 10°CFU/ml) ; OE PRR AY 2 ORR PER OER AE SPE CER-ERER>10°CFU/mD: ©* ill RD (A AEE. SURO. GPE RAT] (PSB) FF BOL RAS] EL Be A / AOE AE Ae R/S RE: OB RL IES | ac PE / LIBR BT PF BB AAS | Da HL BA / SL eT SHS F REL PASE FEU 5 LE ARS | DAL BF Hee a AL EA / HL HE BUH / HOF ORBEA: Out PD ARAL FL H RU (GM) a BI, 3-D WO (G Ehe) HME SE 2 UCPATE. Hh, BHA IFLA 1. ARTI PUA a. JST RRP RPA A SPR, Wwe > AR BE BSBA HERE. FETE PEA AE A PET SO REI ER BURP TER RR CE. UR RR SS, SEK A SURI, PRAISE, SRE TE AOR. FUE See DAE WR JNA ICU PERO, BETTS, OR. PRT TA HE FRA Hd BE. CPLR RR HE. SRL BEE a ce eR AL eo OE. MGR PERRET EP RE, JR OTA IR AD REARS 7K FE, TPM. Co, aE TPAD A De BB BE, FERRER GERRI. TAPP Be Pe EB CE Mh AP ERAT AR MASEL 1, Hi FL HALGHRAM, RTKARP HPA SE URE. (ES) AGL 2, Biby WI ams sj ICU IH We, CE AR) 2. RENN TDT MAF TERRE DY REAM A AA BOLT 2 OT Wa OR PRY Bek: «DDE MEP a RSA A LS 0) Be A ISP HF FE ICU HH FF AE See DEI Hi RAE CRS A MOR A ELAM ATOM ECM RA: AAMC ARMT SHS RBH RSBERS RRA RTLOG SIT (2007) 193 POPE HIV BORA) ET PDT. PDR IAIT MEPS 5c We EA VOT ROR, RAPES GEM lB HY BLA. HAELS, LRA AH SARA RR TRAD ROR ET. (A Bt) ICU ARBOR, WAU UN TEL Aa 48 int, BU ZE ICU et TAREE 72 it. WIE Oh, BREE ATER EF. Hpk IP] AYER. AB FEMA » PRIA PAB TIT HEE AR HE Fe EK, (LEI) Meta OT LAR. BUTEA IK TRI A, (LARS. LIAN fe cE nay. AEM AD ala. LF STAB ASAE He OT IE, REE Sa SSIS 2 BD FEI 5 SCT BEAT SEA ILS BO BA FD ZG AR RS A. PHRELA, ICU HARRAH RA -REBTRADH OMS Fe. (CB) 3. OTE A A EPR PURER TAY ABSHE SEE AE SEE A SBR SR HG eB 2H PE A SL RE! 400mg /d, A RAY SCRE DORA EI A (800mg). 4 LAT HF BRAK ART 25ml/min i}, #8 Bt SE EE 200mg /d. SUBEMEED DK GE FAFA BE AA Jy 200~400mg/d. HRS. ORME SEA SOR. BIBT IAT AL dh SHR 400me/d RA BREMT A 200mg/d. Sy tah > C1 ARIALAY FAR BL I DEBI Be SLAB Ey AE RO BE A RYE 5 BAIL PPE DN ‘lA, “ERRISG ADE YA 7, RRO a > HA eS DF 2S ROR RAE, (SBT — Be HID AY MIFE IM HEUER. TRETRRS, WOES RRR. FP IF OAT, Hae RASHES RAFAEL 50mg/d, DOHERER B RAIA A th EASE RS PEE, ORT Fr. HMR GAS. /\i AMOR R B CO. 2mg/Cke + d)] AY IFT BF LAT EAS. ARAB B ARRAN. DESEO, eT ES LR ae PERE BASU TT WS th RH 24, REG 1~ 1.59, Ane NEE PPUERUAIT , SUREATIN FE Smg/Ckg + dd. MEA PUBE AERA T 5 BF TEER BAR TUARC AT APA TSE, GASB AR. FL Sme/ (kg + d) pute GH BIRR ARR, ARCATA. RULE ALT AS, ATO REMI, Ze TT a NM 2, TEESE Bi EA.194 lemeriEe BRA wy BERS IPL Wier (— TERA HP ROR AEE. AEMANEIAI?, CLIN BIDT ELIOT. a0tE WT. PST RB tea. 1. SURPRISE RPA FEAD IF , ERR RZ Ti. TERRE TA IOHE IAT . SFU REP EME AA ET RE RB. ET ATA AO I, AR. PEE AR ER KF OVEN BS DASE BE BEEP EAE SE Ae PE Pee A OE AS H. PRR ACARHINOR, RRM SAG. IER HAELS: SESW EHREA, GUTBERMAM OT. (ER) 2. SCAT ELI RIOT IF] R.A REAR ATR JESU, (UHGAEE 2 UCHW RB X ST. CT SG. ARR 35, WA SUEAR, SRIF RATT, BURRIS. HET IS 1 fe EAE ASH FAI MAN TL BL BCA ET) RAT 2 BRT F HERE MAY OT ELE. BRAT AN PE FETA IE AMO HE TAT ERE EE A FR, RAP AERE PRICE. ATT AE BES AH SAAT ES HOSEN AT Ft PRG AE OA PE De Sw as AR A ST MT BWA, LIL AR RE. BD-RE ATI PE DNA AY PCR SR. SIGPROER. ACER, TEBE CT AHR. AFT 7. HUE. PONT RMT Be ASS OITA 25 EN ETB ARTE. TM. AUT, UR. HASLG: H1ICU ABA H FL RS RRTASH, Met — HF RARFIEB, (EM) BAER: HICUAWLBRAA, BTRESEM, RRA SHY BB, RTRA MAGA. (CH 3. ERAT FP RPAUFL WD IFT UR. SRT RCP PSE TT EEL BAT. DRRABUN AMR WHE. RAPA MEENIATT. WAT 4k HADIT MIT RASABARRIR AD. AWKFESE OOS. B BAA, FRAC, RAMSAR ee. NOE FELO RRS, ERMA ORE RTE. A ASRD. RORPARER DR. UDR SPR EL SALE MBER, TL as wT PES Ah, PARAS; JMLSTR, FECT ROA A BE HS,REPSRAAABSRVM See (2007) 195 TAFT RUM. TE EM. RSC. EZ TER BSH AIRBAG. AS LAE HRN BAS WRIT, ROR AHEM. HH FSA. Sth ATT AR RATT. (>) BAUER SAAT TCU aE TPT ATE AGE, CECE SAE TES BB TT DY AE RRO ROS AWS LS LE PE EE. TEST AMAL E EES A HL a, FR OT A ie Se wR ob AE PTA AE. SE ICU BRAG A ZALT Ee . 1. HARA A REM BEAR B BE PUNE WMT 32, ML BERITE SS. MOWER A MBER. SEARS PRU BK SS. AURA MAL HE BF PF EA Bs GE Lg SPIER BARREL, PSPERE RE BA AGATE MAES eae, PEED MERE, PARTE ICO aE ES. FY EER B AR KAY PRR EE SAREE Bee Biel, (EET EB AB RSS AS PRY EE RE ABT. EAR RAGE AAP RE AER PK B AR A. JF SAS EE 2 EEE. (EL GRE ICU Ae AG My CA AF EAA TE 9 UA DR UEDA. SBE TP ED A 6 REO A BE Ass Fe BIT RSS PHL BSL SRT 5 RR PE AB PY 9 DE eB Ue). {APEHEST IR T BUH BAUR. JUG ae & eh AA BAR. AT FE ML Ey Ha Be RE 3 HL SO BE aE 9 He MARTON Sete, IPE B AUBERT, (Roe BE AT PR TE i>, SSOP AACE. Sb. LAER REAR ET tt LLL PLN ESL GE, —ALPP EGG OT RE. LIRIAS ORR DRE ACE BR BR S25 EE EE, TS WPSUAE SEE. AAUP TEE BH So IE PEER B BLAU OK EIR BS RIAZREAL, ATSB ALA RES. (ELAR AR BF HAE. RAERE: RABBI ERA BRAT HER VL BS hE Hane Bm, (ER) 2. AP PE REA Ot Ge AG EE CD) FER Ae SN. APA A RG NETS HM PDE Fe PARSE FT AE EI REAR ES. ADMIN Pa REY AR LORS ZG 5 RUTHIE WE 5 ELL bot SLAP SHAE196 laReTem FEET OR RAUB, ARPES. TR TUM DIE. HRP PRCA, SABRE EW ea IC, mA EE. XP ‘pe GI) BFE AAT a AT Gh SL 2 DE PR A PEARS HE PE PDEA BP. BY AE PE TP RZ, BRO, APRA, ZUR SERRE. BAT ACER RPL PP AFORE RTL VOTE. RPE PERE (Child-Pugh 324) 5~6) MAN Ae. HE ISHARES (Child-Pugh #25} 7~9) EWR! 35myg/d, AAT ACE BEBE (Child-Pugh FE4}>>9 4) AREA ATZO ASE. ee AP TEL EA Bie A HEME — Ao RAE LG (2) "PED BE PREAT aM BEDE Int 25 4 9 RS ARE sR 80% els OWS PEREHELH. WUSHEBRAE > SOml/min RY ACRE TARE ZS AL. WUE RRA A AL PR BOPEDAIT TEP ARTE ERR. AERP Mma PCI PEE Hl RE MEMRAM. OACAAX: MAK SAREE OU. A HEPED 96%. TERRE 40~50 I. QAR SAE: AAAT—K 70mg FPF. BG SOme/d HERE, MRERLTA AAD LN, FPR WATE. OUEST: AT ORES AAG A EE ZY 2. KRIRE —RACRERRATE RAIRER, MOR RS WS ALA RR ER TLE, LZ HAY SPR, HERR TL, SEAR ER Ut aR HAT BLE Bit A ELAS A I lB AR WR CHT RR, HURRAH. AE AF SH See BORE SUHBOR, GDR ASHE, MR SARE, ERE. 4B THE. SHAS E >. ERAS BRAT UREA. (EL RIAN Bi. FON TIT BE aR ATE TALE 150me/d, BT IE ML E A SER BORNE TIRED 50me/d. WR He me Oi ME: ROR — 125, BURG ESR BT ee OR. AER. QA AE: CART. ILA SEEM, ZO ANE A MB Hy200 Werks ISR EH Eat TRA MAE, BARA, MATIZ, BARREL GOE ABR. IESE 2.5~5.0 Nt. OAR SR: SAREIEM . PIMA SO~ 150mg/kg (KH) 4 A, BONA LK: BARE, BITE 25mg/ Jeg (A HE CERI Jer FFD 5 a] SO a | Se He EL PAR BE 38] 70~80mg/L. OE BIR. SAMMUT AF 2 Ue. Ta TA ALA DM a AM RP SAFIUAE, “4 SPITE BRAY, PEER B Sek AUMOMEME NTA BHI. (LERBAREAE RAY HA BIT eH (2007) Lie H el ESR BUA MEK % BaP) FOI A RB NAA KA SH Risk RRR wee #1 CWH, CWHD &% CVWHOF 33 IHD it 2s eH Bwmsm CWH CWE 5 CVVEDF HO oem 200~ 400mg, 241) 400~- 800mg, H 24h FORMM BASS HR HR RB RLY arekg KE, ORR, 4meke AE, OR, 12 YR 12K Pee — _ MBAS Fea ARRAS BRC HBR GRA O4~1.0meks KH, 0.4~1. Ireks AB, AE B12 Y—R 12 WMBR CIR 2~Sreks KE, GB 3~Sreks he, F san 241 R 241 IT —R ABR CIR = 3 ~ Sm ke KE, 3 ~ Smee hE, 241i 2A dN te: CVVH: ZScRN ADDI ARIER, CVVED, ESE NPB RD RELHESTs CVVHDE, 2: Se RP BKM ik Me HF BBdts THD , MLHeM WLM, CVVH, CVVHD aR CVVHDF at, ati, Ain 1L/h BER 1. Martin GS, Mannino DM, Eaton S, et al. The Epidemiology of Sepsis in the United States from 1979 through 2000. N Engl J Med, 2003, 348; 1546-1554, 2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals; a three-year analysis. Clin Infect Dis, 1999, 29; 239-244.BESSRACMBERCGSTEG (2007) 201 3. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis, 1998, 27: 781-788. 4. Slavin MA, Australian Mycology Interest Group. The epidemiology of candidaemia and mould Infectious in Australia. J Antimicrob Chemother, 2002, 49 Sl; 3-9. » Kauffman CA, Fungal Infections, 2006, 3 (1); 35-40. 6. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidemia in europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital- based surveillance study. Eur J Clin Microbiol Infect Dis, 2004, 23 (4); 317-322. 7. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med, 2004, 170: 621-625. 8. Denning DW. Aspergillosis in nonimmunocompromised critically ill patients. Am J Re- spir Crit Care Med, 2004, 170; 580-581. 9. Garnacho-Montero J, Amays-Villar Ry Ortiz-Leyba C, et al Isolation of Aspergillus spp. from the respiratory tract in criticallyill patients: risk factors, clinical presenta- tion and outcome. Crit Care, 2005, 9: R191-199. 10. Lewis M, Kallenbach J, Ruff P, et al. Invasive pulmonary aspergillosis complicating influenza A pneumonia in a previously healthy patient. Chest, 1985, 87: 691-693, ll. Karam GH, Griffin FM. Invasive pulmonary aspergillo: nonneutropenic hosts. Rev Infect Dis, 1986, 8: 357-363. 12, Valles J, Mesalles E, Mariscal D, et al. A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. Intensive Care Med, 2003, 29; 1981-1988. 13, Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isola- in nonimmunocompromised, tion from respiratory tract samples in critically ill patients. Critical Care, 2006, 10 (D; R31 14. Vandewoude KH, Vogelaers D, Blot SL Aspergillosis in the ICU—The new 2ist century problem?, 2006, 44 Suppl: 71-76. 15, Hartemink KJ, Paul MA, Spijkstra JJ, et al. Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med, 2003, 29; 2068-2071. 16. Ascioglu S. Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infec- tions in immunocompromised patients with cancer and hematopoietic stem cell trans- plants: an international consensus. Clin Infect Dis, 2002, 34; 7-14. 17. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the Management of Intra- vascular Catheter-Related Infections. Clin Infect Dis, 2001, 32; 1249-1272. 18. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med, 2006, 34 (3); 730-737. 19. Ho KM, Rochford SA, John G. The use of topical nonabsorbable gastrointestinal an-202 emetem BREA 20. 21. 22. 23, 24. 25, 26. 27. 28, 29, 30. 31. 32, tifungal prophylaxis to prevent fungal infections in critically ill immunocompetent pa- tients: A meta-analysis, 2005, 33 (10); 2383-2392. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin In- fect Dis, 2004, 38, 161-189. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic Fluconazole in Liver Transplant Recipients Ann Intern Med, 1999, 131; 729-737. Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome.J Am Coll Surg, 1996, 183 (4); 307-316. Singh N, Paterson DL. Aspergillus Infections in Transplant Recipients. Clinical micro- biology reviews, 2005, 18 (1); 44-69. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med, 2004, 32 (42), 2443-2449, Vardakas KZ, Samonis G, Michalopoulos A, et al. Antifungal prophylaxis with az- oles in high-risk, surgical intensive care unit patients; A meta-analysis of random- ized, placebo-controlled trial. Crit Care Med, 2006, 34 (4); 1216-1224. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically ill Surgical Patients. Annals of Surgery, 2001, 233 (4), 542-548. Garbino J, Lew DP, Romand JA, et al. Prevention of severe Candida infections in nonneutropenicy high-risk, critically ill patients; a randomized, double-blind, pla- ccbo-controlled trial in patients treated by selective digestive decontamina- tion, Intensive Care Med, 2002, 28 (12); 1708-1717. Jacobs S, Price Evans DA, Tariq M, ot al. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med, 2003, 31 (7): 1938-1946. Philippe E, Patrick F, Jacques B, et al. Fluconazole prophylaxis prevents intra-ab- dominal candidiasis in high-risk surgical patients. Critical Care Medicine, 1999, 27 (6), 1066-1072. Potter M. Strategies for managing systemic fungal infection and the place of itracon- azole. Journal of Antimicrobial Chemotherapy, 2005, 56Suppl (SL): i49-i54. Husain S, Paterson DL, Studer S, et al, Voriconazole prophylaxis in lung transplant recipients. Am J Transplant, 2006, 6 (12); 3008-3016. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis. a- mong allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis, 2006, 55 (3); 209-212.33. 34. 36. 37. 38. 39. 40. 41, 42, 43. 44. BTESRACABERCU STIR (2007) 203 Mattiuzzi GN, Alvarado G, Giles FJ, et al: Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malig- nancies. Antimicrob Agents Chemother, 2006, 50 (1); 143-147. van Burik JA, Ratanatharathorn V, Stepan DE, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Under- going Hematopoietic Stem Cell Transplantation. Clinical Infections Diseases, 2004, 39; 1407-1416. Rousey SR, Russler $, Gottlicb M, ct al. Low-dose amphotericin B prophylaxis a- gainst invasive Aspergillus infections in allogeneic marrow transplantation The Ameri- can Journal of Medicine, 1991, 91 (5): 484-492. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (Ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double blind, placebo-controlled study. Bone Marrow Transplantation, 1999, 23: 163-168. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of am- photericin B in high-risk patients. J Antimicrob Chemother, 2003, 52 (5): 813-819. Singh N, Paterson DL, Gayowski T, et al- Preemptive prophylaxis with a lipid prep- aration of amphotericin B for invasive fungal infections in liver transplant recipients re- quiring renal replacement therapy. Transplantation, 2001, 71 (7); 910-913. Lopez-Medrano F, Diaz-Pedroche C, Lumbreras C, et al. Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipi ents. Rev Esp Quimioter, 2005, 18 (1); 14-20. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Di- agnostic Adjuncts. Clinical Infectious Diseases, 2007, 44: 402-409. Marr KA. Empirical antifungail therapy —new options, new tradeoffs. N Engl J Med. 2002, 346; 278-280. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients a pragmatic, multicentre, prospective and randomized clinical trial. Eur J Cancer, 1996, 32A (5); 814-820. Malik IA, Moid I, A; photericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med, 1998, 105 (6); 478-483. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of Z, et al. A randomized comparison of fluconazole with am-204 acRDeTam HE IR EAM 46. 47. 48. 49. fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med, 2000, 108 (4); 282-289. . Boogaerts M, Winston DJ, Bow E, et al. Intravenous and oral itraconazole versus in- travenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacteri- al therapy. Ann Intern Med, 2001, 135; 412-422. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal am- photericin B for empirical antifungal therapy in patients with neutropenia and persis tent fever. N Engl J Med, 2002, 346, 225-234. Walsh TJ, Teppler Hy Donowitz GR, et al. Caspofungin versus liposomal amphoter- icin B for empirical antifungal therapy in patients with persistent fever and neutrope- nia. N Engl ] Med, 2004, 351; 1391-1402. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med, 1999, 340: 164-71. Cordonnier C, Pautas Cy Maury S, et al. Empirical Versus Pre-Emptive Antifungal Therapy in High-Risk Febrile Neutropenic Patients: A Prospective Randomized Study. Blood, 2006, 108; Abstract 2019. . Schwarzinger M, Beauchamp C, Maury S, et al. Empirical Versus PreEmptive Anti- fungal Therapy in High-Risk Febrile Neutropenic Patients: An Economic Analysis. Blood, 2006, 108; Abstract 2021. . Maertens J, Deeren D, Dierickx D, et al. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis, 2006, 19 (6); 551-556. - Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 2002, 347: 408-415. . Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutrope- nia-associated invasive fungal infections. Br J Haematol, 1998, 103; 205-212. | Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, con- trolled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis, 2002, 35: 359-366. . Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treat- ment of invasive aspergillosis in patients refractory to or intolerant of conventional an- tifungal therapy. Clin Infect Dis, 2004, 39; 1563-1571. . _Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of inva-EESSRRCMSSRVM STIS (2007) 205 60. 61. 62. 63. 64. 66. 67. 68. 69. sive aspergillosis in patients with hematologic malignancies. Cancer, 2003, 98; 292-299. . Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis, 2004, 39, 797-802. 3. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis, 2000, 30; 696-709. . Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J, 2004, 34; 92-200. John RW, Helen L. A New Era of Antifungal Therapy. Biology of Blood and Marrow Transplantation, 2004, 10; 73-90. Girois SB, Chapuis F, Decullier E, et al. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis, 2006, 25; 138-149. Dismukes WE. Introduction to Antifungal Drugs. Clinical Infectious Diseases, 2000, 30; 653-665. Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Current Opinion in Inves- tigational Drugs, 2005, 6; 170-177. Bekersky 1, Fielding RM, Dressler DE. Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Lipasomal Amphotericin B (AmBisome) and Amphotericin B Deoxy- cholate. Antimicrobial Agents And Chemotherapy, 2002, 834-840. » Walsh TJ, Hiemenz JA, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis, 1998, 26: 1383-1396. Heinemann V, Bosse Dy Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother, 1997, 41; 1275-1280, Clark AD, McKendrick S, Tansey PJ. Comparative analysis of lipid-complexed and li- posomal amphotericin B preparations in haematological oncology. Br J Haematol, 1998, 103; 198-204, Garcia LA, Duque A, Castellsague J, et al. Acohort Studyon the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol, 1999, 48; 847-852. Townsend R, Hebert M, Dessimoz M, et al. Pharmacokinetics, (PK) of micafun- gins an echinocandin antifungal, in subjects with moderate hepatic dysfunction (MHD) «J Clin Pharmaco, 2002, 42; 1054-1059.206 ime BEE ea 70. 71. TR. 73. 74. 6. 1. 78. 79. 80. 81. 82. 83. Pettengell Ks Mynhardt J, Kluyts T, et al. Successful treatment of esophageal candi- diasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol, 2004, 36: 372. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxy- cholate infused over 4 or 24 hours; randomized controlled trial. Br Med J, 2001, 322; 579-582. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of ampho- tericin B deoxycholate: an open-label observational study. Clin Infect Dis, 2003. 36: 943-951. Speich R, Dutly A, Naef R, et al. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly, 2002, 132; 455-458. Klastersky J. Antifungal therapy in patients with fever and neutropenia—more rational and less empirical? N Engl J Med, 2004, 351; 1445-1447. . Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in pa- tients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis, 1999, 29; 1402-1407. Dimitrios P Kontoyiannis, Russell E Lewis. Caspofungin versus Liposomal Amphoter- icin B for Empirical Therapy N Engl J Med, 2005. 352: 410- 414. Joy MS, Matzke GR, Armstrong DK, et al. A Primer on Continuous Renal Replace- ¥ 362-375. Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill ment Therapy for Critically Ill Patients. Ann Pharmacother, 1998, 3 adult patients receiving continuous renal replacement therapy. Clin Infect Dis, 2005. 8: 1159-1166. Mobr JF, Finkel KW, John H, et al. Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients. Journal of Antimicrobial Chemotherapy, 2004, 48: 3151-3153. Steinbach WJ, Stevens DA. Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis. Clinical Infectious Diseases, 2003, 37: $157-187. Giles FJ. Monocyte macrophages, granulocytemacrophage colony stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin Infect Dis, 1998, 26; 1282-1289. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis, 1990, 12; 1147-1201. Habicht JM, Passweg J, Kuhne T, eval. Successful local excision and long-term sur- vival for invasive pulmonary aspergillosis during neutropenia after bone marrow trans-BECSRRHABSRVM STM (2007) 207 84. 86. 87. 88. 89. 90. 91 92. 93. 94, 95. 96. 97. plantation. Journal of Thoracic and Cardiovascular Surgery, 2000, 119, 1286-1287. Stammberger H. Endoscopic surgery for mycotic and chronic recurring sinusitis. Ann Otol Rhinol Laryngol Suppl, 1985, 119; 1-11. . Wiatrak BJ, Wilging P, Myer CM, et al. Functional endoscopic sinus surgery in the immunocompromised child. Otolaryngol Head Neck Surg, 1991, 105; 818-825. Muchreke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-term antifungal thera- py for fungal prosthetic valve endocarditis. Ann Thorac Surg, 1995,°60; 538-543. Craven DE, Barber TW, Steget KA, et al. Nosocomial pneumonia in the 1990: Up- date of epidemiology and risk factors. Seninars in Respiratory Infection, 1990, 5 (3): 197. Perfect JR, Cox GM. Lee JY, et al, The impact of culture isolation of Aspergillus spe- cies; a hospital-based survey of aspergillosis. Clin Infect Dis, 2001, 33; 1824-1833. Rees JR, Pinner RW, Hajich RA, et al. The epidemiological features of invasive my- cotic infections in the San Francisco Bay area, 1992-1993; results of population-based laboratory active surveillance. Clin Infect Dis, 1998, 27; 1138-1147, Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients; a retro- spective case-control study. Arch Surg, 1999, 134; 657-664; discussion 664-665. Hoerauf A, Hammer $, Muller-Myhsok B, et al. Intra-abdominal Candida infection during acute necretizing pancreatitis has a high prevalence and is associated with in- “are Med, 1998, 26 (12); 2010-2015. de Vera F, Martinez JF, Clara Verdu R, et al. Pancreatic abscess caused by Candida following wide-spectrum antibiotic treatment. Gastroenterol Hepatol, 1998, 21 (4)+ 188-190. Vandewoude K, Colardyn F, Verschracgen G, et al. Clinical relevance of positive as~ creased mortality. Crit pergillus cultures in respiratory tract secretions in ICU patients. Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy, Oc- tober 30-November 2, 20045 Washington, DC. Abstract K-1440. Blumberg HM, Jarvis WR. Soucie JM, et al. Risk factors for candidal bloodstream infec- tions in surgical intensive care unit patients; the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis, 2001, 33; 177-186. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg, 1994, 220 (6); 751-758. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med, 2006, 34 (3): 857-863. Petri MG, Konig J, Moecke HP, et al. Epidemiology of invasive mycosis in ICU pa- tients; a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research, Inten-208 BRBGER BER DA sive Care Med, 1997, 23 (3); 317-325. 98. Linda W Kam, Jason D. Management of systemic candidal infections in the intensive care unit. Am J Health-Syst Pharm, 2002, 59; 33-41. 99. Wey SB, Motomi M, Pfaller MA, et al. demia, Arch Intern Med, 1989, 149, 2349-2353. 100. Vandewoude K, Blot S, Benoit D, et al. Invasive aspergillosis in critically ill pa~ isk factors for hospital acquired candi tients: analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004, 59, 251-257. 101. Pittet D, Huguenin T, Dharan S, et al. Unusual cause of lethal pulmonary aspergil- losis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1996, 154 (2Pt1); 541-544. 102. Rello J, Esandi ME, Mari with chror al D, et al. Invasive pulmonaryaspergillosis in patients obstructive pulmonary disease: report of eight cases and review. Infect Dis, 1998, 26: 1473-1475. 103. Bulpa PA, Dive AM, Garrino MG, et al. Chronic obstructive pulmonary disease pa~ tients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med, 2001, 27; 59-67. 104. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections, Lan- cet, 2003, 362; 1828-1838. 105. Crean JM, Niederman MS, Fein AM, et al. Rapidly progressive respiratory failure due to Aspergillus pneumoni py. Crit Care Med, 1992, 20; 148-150. 106. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax, 1991, 46; 15-20. 107. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidi- asis. Clin Infect Dis, 2000, 30; 662-678. . 108. Vincent JL, Ansissie E, Bruining H, et al. Epidemiology, diagnosis and treatment a complication of short-term corticosteroid thera~ of systemic Candida infection in surgical patients under intensive care. Intensive Care Med, 1998, 24, 206-216. OS, fH PAY Zi aks et BS Bk Se «LARC / EER A RD BR TRE SIT JW CD. PARABLARR. 2005, 44, 554-556, 110. ARAB REE AS. BRERA RRR STATE CRIED . fh ABV ARaR. 2006, 45 (8): 697-700. lL Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non2Candida fungal infections after liver transplantation. Transplantation, 1996, 62 (7); 926-934. 112, Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lungBESS RACASRROM STI (2007) 209 113. 114. 115. 116. 117. 118. 11g. 120. 12. 122, aspergillosis and the significance of positive aspergillus culture after liver transplanta~ tion, J Infect Dis, 1992, 166, 1379-1383. Ruffini E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation, Incidence, risk factors and prognostic significance. Sarcoidosis Vase Diffuse Lung Dis, 2001, 18 (2); 181-190. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive as pergillosis. Am J Respir Crit Care Med, 2006, 173 (7): 707-717. Paterson DL, Singh N. Invasive aspergillosis in transplant recipient timore), 1999, 78; 123-138. » Medicine (Bal- Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute indings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology, 1985, 157; 611-614. Greene RE, Schlamm HT, Stark P, et al. Radiological findings in acute invasive leukemia: characteris pulmonary aspergillosis: utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of invasive pulmonary aspergillosis in high-risk patients. Clin Microbiol Infect, 2003, 9 (Suppl 1); 0397. Munoz P, Guinea J, Bouza E. Update on invasive aspergillosis; clinical and diagnos- tic aspects. Clin Microbiol Infect, 2008, 12 (suppl 7): 24-39. TAAL ABER BC) BE Be ALR Ye MS TBI. BE BEAR UR ASE ER ME - dE BE BE RE AeA, 1990, 6 (5); 306. Schimmelpfennig C, Naumann R, Zuberbier T, et al. Skin involvement as the first manifestation of systemicaspergillosis in patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 2001, 27: 758-755. Schelenz S, Goldsmith DJ. Aspergillus endophthalmitis; an unusual complication of disseminated infection in renal transplant patients. J Infect, 2003, 47: 336-343. Chamilos G, Komtoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol, 2006, 44 Suppl: 163-172.(KMSSAR SABA (2007) PREFSEERERS 1 ABR LS A FE EA FS | LB ASE OT SF AS BES APR LAER, SSUES AL Ad PEE AL A BE 3 A A. HE 304838, (RM ARR SETA ER AUER, SRT, SUI RSE EY SRABEBO 8, AML ARE AR VE AS Se BE A SE PE A BAC HR 2A FEEL GFF BAY & 8 AER AE (MODS), AT, AR MLE HRA SESS BE 4 A EAD Re FE EY. GA FR a FB A A TA, PERSE SE iL, Ol Os SP BC Ae a He ASE EH oO Hs AB ET PB 10%~40K%E~9, AUG LEE AC 5 4) aS Ba kg A SR SURMLE. FES CASY I, FLITE TE, FART RABARS. e 2EEB MODSS~?), fi nh Ze EA HE A ES 2 Jd A A EHS TA Be, BEG HERI ARI EA RTE FRED A SE a AO, PSR SL A FEL Te «A ic a 21 A SE, A RG ER ST DRE. RHE P GE IK MS A SET EAE, ERIS WE DAB ATT ROSE L . LCRISP AR LACE ARE BY I I A HERESUBIRGE Delphi 80K iL D. 1 HEEMB) SHASTARAY Delph! BR A 28 2 R1 RIRBR 8 RAI 1 LT RATA ° AURORA o BAYS 1 TD || SHS RS — (QBN OR V AA RSS 210{IMB RATE BIE (2007) 211 Ee FARLAADD I AREA, REO, GIT, PADMA RANDOM T MED. RENUAR, GONE, FRAMED (St) ARB IULETROUREE fl SERENL, GRAS Vv TREN, DEMRARUSRAM Vv BORE, I NRAANSSSD HEEL 1: MEME MADESARAREE. (EM) 2 SET AR LAE GE AEE IE EER AE BEB. BEER PAE AER ERS, KM MY A PEE. WENT. RRR Ett. AG. TEAK TREY pC ES HOSEA Oh HERAT ret, BES. Bik, PRAT B. AR GPE AER OE HERE KAMER RLS, ERA GAARA A A at NE HH BR A REA TES PIL BAW AT RNAS GE EMA SD EG"), AL ZEEE AE OS ESI TR BS ZB BE, FE TE BET BR HEAR, PRE. GLE HCAR, BERRI. WHER FRE (<90mmHeg ak BE RHI FRET 40mmHg) aR AKFR RD (-<20mmHg), FREE<0. 5ml/(kg + bh), DAB > 100 U/ Sh, PU RBKIE (CVP) 30 BEA HM 780~150015~30 > 100 Fe 20~30 20~30 CHIR M —1800~2000 30~40 > 120 BE 30~40 5~ 15 Be NW >2000 40 140 Re 40 TR SE TRAGER 2, RAD WAAR ATR to SEAR LH PM A OR Be. (CR) HEELI, RMRSKAWH EMS, BREA HAMA Mak RM, CE RR) 3 i PAE BB FRAP FEE EAR RUA EAE TEE — BABA BBL» FRM. AERP PACEHE «(REAL , i EC BE AR OP CL AR ML FE Hat BAS RASPES OF» JL AR Re RS NEE HIS EE EMU BEB ILS Se UME i HP i AR eMC AE TE ASS LF FL, BEST MALEK + EAL EE AUS 25 Ca SP BO EPA KS AI ATT AE VBI Sk EID A FE aA PE TL PE 5 SATE a E. JLAR RST FO VU A aR, KR, OEE BI. AR oi AEE OP A A RE LAA AE, PETAL Se Hn, Ian SUE FBSA EHP ODT A RR «TIN PE “AVE IVA (HE, TIL. WR TRE. RARE LER EE REO HE AE» PRUE OBS FS ML REE PE 9 Th AB LPR DAL BO IE AE A RT ELH ‘8 AL SF BEE A FP Pe SIS A SBC DAL SF BE a PR SEED RIE» LR MAR RT Se HT RE RAS AS BL SUG ABA 5 AC AAL HA RL Ly ARMM BERS RA AE CAPA HEE RE ME AR ES. SRB PA IMLPT EL FBS EAE AS, Fae AA AT A eR AYE FE LAE 5 LFEPA 5 PT GAG Be RR ET TA RE EP 5 AR EN, UPTIGHT BR See ER, TRE FEE IN Jen SIA ER) AN LSP AR BD DB AT RE} SLESPUD TT LE RAG BEDN TEIN Hil, A TSE BU Ae. MLR EE ALG EI EB TL LP EE ML HERE LIA OT BB AC Eg i A AE ALSUARDR EPEAT = ARTE NT TEE, ELIE PUA, PRAT AE, ACER, SBRRIR AF CATP) AE at HAD, FLEE SSMS PER, PALA RP AE. METH AA SH AE EE i BB TE Oe AN EB, ECB HE MODS, HFELA: RESOKRMESHKABEP EPHELR RS Fi saree WRG. CE ML) 4 HBAS SSA RE AGUA ASE RY. LP A REP. SPB RED ATE DO: BER. SFL HEA SE TTT, DO. F REFERER FE at, FADE HEC AT ARE OF. PE AM MAE ERE. DO. TP BRIT, VOo FEAST BE FATE. PARE BOS RS ey EK (OPER) Fah AGRAWAL, “4 DO, AREER, SURETY VO, BEBE ARAR EF ANZE. DOz FES — se PALES » BIE PUR H SSE, LAS EA AE HE. LEC FREY, SS HE (PaO, ) eh ai Se Be a eA, ETT Sm DO, . PA» aL SEL SAL eR sR FERIA Set EIR AB BB BGA EET TL IK Csu- pranormal DO;) Wy Sd 9h FARA OASE» RASA HT VANE PARE 1B Ki, WAHAMRA, SPER ABA AO A Ae. AIRE BEARSETS AS, ADEE PAE ERE LO, BEARS Dy fe Sede HE, THOM Kern HO LBL BT RA RCT ARIE Be, PE BR AED BH BT, RSIS AT ABRSE LAS, MRC TE a BAT AT PEELS: KASERAPMLELRY, KA MODSRALHRY KERMA, (CA) 5 eal eS ASME AUT A AER AAS BEA SA OR ALDEN AH TE, BA Pa AMALT, WARES AAT). BOAR MM BUR. 5.1 — tlh JR Me Bl GLIA BLS (878, D3, MUR. DRE AUTRES. PRT. Bete214 BROTER She P a HERR TERE FAT ELE EMEA PO BARA. RAB. BOREAL. Be F FE RE BEG EI PR ESR AR EE PIE REAR AN PRINS CEREAL ORANGE ALA FE PWR — LR NE FUR A EP UT SEA HORSE AY L425 SHS I IE REPS R AIK UL. (LALA ERE NB ALFA SJB Fg AS AA AC a RECRAT RR DEULIE ME. ARSE SCH MT ACHE a tH MA FR ER AER “FC PEAR FE” (permissive hypotention)*), 98TH. PF ACA HPE ARC MLTR FE 3 1 AERP FE bart. POS aM He A PLA af SEE Ta] 1 AE TA EDS» 1 PHAN eRe. Ae OTF, AEREE SY HK CMAP) #& 60~ 80mmHg HB PT, RAR AL Se PE ET A. PT DATE RR AS. YR 0. Sml/Ckg + h) Ff, ME SREUE TIA SOS. BERRI LL AH BPR BE TT > RASTER 5 US ALA ALS BE HL ip SH HE HE BR Pei EUR L oP E, EI REO IRR ATS | WL TRALEE. SMA <34°CAY, RPE MLD AERO OO 5.2 AA) ME oh A Be 5.2.1 MAP Hal A MSNA CBP) #2 6@)Z0 KLE (NIBP) f% 5~ 20 mmHg. FPS MORAY, NIBP WU EMEA MEDH EASE BRAKES Ti TBP MUR BEN FTE. PYRE SE mH AAU AR A. Ub. IBP wy HEE DR mI. 5.2.2 CVP #1 PAWP a) CVP EER TIN. BPR MMR, 5 PAWP SA SCHIUE. FAP a Hii it Fy 28 AR AS AGE SAP. A TL WAKO IRIE, RIT IT. CVP Al PAWP Weill #T By Pete ak PERE HED DIRE AN ETA OATS. OFLA A NO HM EL Eo EERKARS ARAN, LWA RWB, CVP A PAWP SOM AT EL PRAT EAE ED. 5.2.3 CO MSV eM tke. COS SV AA AR REREREIRO, 340 Hb AEM COS] SV, i WAP hy AS PaO 2S BE SG EG RGR DD ERAS. PREM Zh, ARIAS LEE AS. EEDA ES AUR Be4C4 CSPVIOT, feat EA CSV, BRIE ZEAL (PPV). ILE SE Aik CEVLW)°*. ORE ALBA CITBV) AO BREE. AE PORE BE A es OY BE AAT. TO FEA, EA SPV. SVV 45MMAR (2007) 215 PPV FY EAA SB OFAN ERR ASE OTE I PORTA E. (EA— PE Is RS A A MABE. Ph LTA LAS RA. HEA EAB TE FEWER AD ATP ARAS AT CA TRB DENRA P A. ESCHER RL, RRERU PSR, ARR, HOES AHIR. CTRL. Zen iK Waa FR RAELG, KREEKLABABES FH RAAF EM ASR HR. (ER) RHEL? HTHERREMA, BANA ARRE LM, (EA) 5.3 RAE el AA SEES RAS RA ER ADEA HEED ACR EAE TRA GE ASTP AAT SR «FADE ARSE BSI a LIB BAD ML BL I SP (LE CUARAS AE. (2 FEII ME DUA REAR AE A SA BR BRINE, Web, Peet S ae AP UE Baty si SSF a PR a Ht SAGAMORE. Alt. APLAR sei AT ee AP SoS SHEE HR (DO. VO. ILFLIB. SvO. 2% ScvO, 4) VAS a RRA SHE HEAR AN SAE pH ffl (pHi) 45 PeCO, SE AAREA WIR X. 5.3.1 BRBAMME (SpO,) SpO, ERRMAARA, WHEEL PRA AMETEARAS . ARMAS RRA TE AO IA 0 FE AER IL. DOT a AS A MDE AEA) F RELA F a ETE ESS STAR, BLUE] SpO. HO ATREEM . 5.3.2 BBM AST ARES DK ML PT AR. FT A AS YO TA OL HE WE, Beefy TERME, VUE LSB, WR A aT (Re Be PL AR BY KF EE PBR AA BE MLAS LI BRR: FE, BRA PLL AEE, BGR ML PLP Ee EAU A Ve EE BE FLO 5 5.3.3 DO:, SvO, RYLEY =DO,, SvO. FY fey PF tA AG at AR Pk 3 RRA LTE. AS MMA BEKO, ScvOz 15 SvO2 A — FE HALE HE BUA EAR PIE ESC RAE SP Bi RU FREE A TEAR PS SO A BP Hi. (ARE, DO, , SvO, XE MLA ARTE HA SE OG HH SF OME RH EE Bee 5.3.4 SOAR AM FLAY Ay LPL ARYA SRE AE A 0 EA OH PRL, BK MAL HG rs EBA Te TE BG BR, SSE AS Hh PLL, BAL BRE LOM TSE A, ER. A RA RH216 lame TE HERA R JAW ARE EO, LA, PLU REE ST LF HEP HERA MELA FES) RAR AAR AS. DEFER AN. FER DR mE oe BG Acs PLEA es A OF Be ae FL OR AG BE LV BR ES Ae AYE 48 . 5.3.5 pHi 0 PgCO, AYER) pHi Al PgCO, fies Jz wk We Se A aE PENOLA EAS | PUTRI ZR RAR AS MEERA Vr A Bia RA A — eR, AER S: TR ME SR RA, BM FLV BERR RE HAE atl, (CA) 5.4 eS oR 5.4.1 LM SARE AT. ZEA Cb) Be A F CHet) ABARAT MLA ARR RE, A MA A SE FOAL A TERR BSS MA. ABER), Hot Ze 4 AF BE LOHR A ate Ht. 5.4.2 RRS SRE Xt PLANE SAT +o) EE. 5.4.3 BEMIARE MS ZE PRE RU BILE TT BE MAES WN, Tee PRS 4 A FARRAR BE ORE. BAUM HE OTs DT 3X, BEMAC ERAT CPT). TAAL ARS} SEMEL] CAPTT). BPR eRe CE EE ffi CINR) #1 DAK. UESh, BMI AMI (TEG) 4", 6 ir 6.1 AH ARSE IIT SAY SAEs HB OR GS Ek SH Re MUA TERESEFETE, UBER ARSENE. AO ROBE BR AHS 3b dn HE. FU, SRAENRARE KAT MARAE. 2) PRA MESA. AP OG ETEK LE ABER BA, ZOUPFE ROS OT REGS Ot ZS BEAE Be HEP OR AO i 2 EIU BERPPETE AES | AT HEFE AR, TRA METT 60 SBP RU TD Se ce Rl AS IVE» PU DLR AEG A EA HEA PETROS. FORE AS AY TALIA BT AE EPR BIT A GR MEA EER RIERA, FF LT AE A OO . EEA OSE A LR MATERA, SUIT AR AE iseMSR AIA (2007) 217 WE, —7MUFR 271 BIMBO BTC. FUR bm TS TE BROT PP FEAE DCL EER DE FCT RE HM BA IRA, DEP Fy Re. UST RE ETT ARI. ARATE BAS. xt BBN EG FNL SRP BG 9 FAA ME HEI A PRLS BT A A PLATT WHER PARSE ES); A DESEESS: CT Reve LER AT A aE CRE SE ARERHETO RELI: PAH ERRSSALH AA ABH RARE. (DM) HAE: SFR MAMA, AAS MEK MMR LMA, MAR MAF ARS AGE Mm, (DA) MAEM: Bik Al G4 Ho CT FRAAHSALEAA, HE SiMe AERA, ABBR MH RBA, (DM) 6.2 RAR WAS IR TAIT YT Le PRR PAPER CAE BE OK ALP ERPS FAURE STEYR CUE BE LA BRAS) EF 56 Sai BREA YF BR PA AHERE FURR IBIT 6.2.1 SARTRE KSAT A FA AA A ED ok APL. HE ROLF. ATEN AUG SET mE SRE A, 297 25 20 FF BE A, WAFEAR 7516 MUSA ML EE ST Bak PRL 5 AG A PR tA A RS PRE FPR, AAG HS IR EPP BEE AY FBR TR] ANS ot BA 7k. A. (ARE, FABIA IS RA EE ES. Sb, ABR Ok ORE AL BEE, (ARAM, ASENS RAE PO, FLAY REET UE, AL. AT. SRT PLT EDFA ACHE, ACER EE PLM RIE TAS BET FLAK 0 , ETRE HY LON TTA LRT 20 thé 80 4E(R. ARTA FEE PAY SAE Ey 400~2400mmol/L, EAE IIE TE (4 Fas TK HE YE HELA WB th He BT TEA! CHISD?. 5% NaC]+6% dextran70), PBEM CHS7.5%. 5% RR 3. SOUL) B11. 24 SLR, FOLATE RRR, eM HSD FAR REF HS AE BHO, (HE, ETS SE BEAR MA), ES tk eT EG OE BR EE TED SR PR PE PPR SEA A AUR A PR ARON Te OC (Ha EA WTA, AMR, MMR PF. BE HSD Al HS By ee AL WBA AUD FE AE BIS BRE AAS GI WL BIS A II FOR A AVOPIE TE EET PAGE TARP MLE AER. BUA AIE218 ISReTIER EER EAE WESTER PAIRS See DEA RPE AM PA A eR TE AE Fa FY PARR FS ya AS J BC RL We SRG PT A A AY BATS, AEA, Lar i he A FB BP EF 9 TE BRE RENCE | ARR SCE YEE AR SE EO RE AS BE PEE TTS AURIS, (ALERTS PASI BOE BAR, 6.2.2 RAR ABARAT Hit. GAA, BOM BE). RE ATARI ALM MS AS AR MLA BR EEF 0 A ERARCEEH MASA FEC SRGEBY CHES) SAT 4r SBP a. AB Td 2S 2 5 A SEE BASS FA TE. RH 6 EE, TBR 300mOsm/L, #ZE 1L FEZ HERE ES ALBA BH in 700~ 1000ml, AAE PARA AE MPRA. TSCA AT PAR. HY A WARE BUSMT TO], AC ARRERCEIK A ESS PAR, OPT cata, IRR UR, APPAR. ARV, HES FIFRA, IRR PE MTL PE A BETAS 5 PRE BE wae LAR At PA Be FH HB OF RRA), CEASE ED TAT, RT PDN EE, OL, Bape BU, LAA EE, APR CE SOT ARE MUR RELAIS, ZN MUIR, APF) FURR. 1A C2/C6 BoA Fea IS Z, BEBE A AT AE BE LD BE BE Ay S-) FA BUI ARIZ FS A LIBEL EAA ORE, AB AY GAAS RAY FAK. Ba PSE RL BE PRE ASD HATS RZ RD AT AS EAE FERRE A 22IR, MEME, Se AEB, MBE 12: BMALKARTLEM, RZEKRRMALKRAMHRSM A. (CA) AAR MAR RR, PETE A PRA TO BAIS HER 75%~80%. ARAM FARA 66 000~69 000, AAT, Aim See tlm A 4%. SH. 10%, 20% A 25% ILA MBE, WKAR, FAR JEWS HR PERS tS ROB AE EER CPE SR Pa FEF RSCG. CELT OR ER a ES EY PEE LOO 6.2.3 SERRA ALLER AUER MBER PARC EU PU SSD SNe FB FAA EMBER, ERA AAAS LB RA]. PEACH, SOLAR CAR PR AUB SRC ESE I TROP EL, EATAB ET SRT REAR MES. AERA. MPO. MAP RA(RMS SHAPERS (2007) 219 COTA, IBIAS TRE PBF ARPES WBE SL TENT TE AS BB AT HAE EI AS PAL apg ts Ret SPAT ARS» FR AEE APRA MG He 9 ZH SE TT. Fe TENI AI AEE FEDER TA] A 28 ASOT Me Ie a AY EL SAE Re RE ES AA Te, Bak BA, PP ARG AE OA EIA A BBR EL ASD] A TIE SP SAPD RH AA BATS TSE 5 TA EP Ee AA ee ATL. EI, FV ABUA AAMT DRIFT RO | RS AER A. I APRA A UE AA aE, FT ARR, DEE a PATE SUB a AT EATS SG EKO, A SEF AA A LIB TAS EM ET, AT REE FA? 5 AL HP RGB AT ARE SA FP A BE HEAT A AL i REE. AALS, AH, HARGHERAN MARS MARAT RHEE KARAL EG TRG SA A RAM LA. (CH) 6.2.4 SAAR AN TE 1) TERIAL RAE BEE «(PRL EEA SEEN ETI SE AS «HBL SIE RB EVADE ALR, VACHSS PAG, PRE FEE Sf TS MP IAS PL NK SEE LA i AE CEA IALAE ASS FEE AE I A BEE BEATE PEEL. DRA ALTER, 20 Riek a rae. (ESD (2) FART. AON. A er A AE Tar SH RPS BE 4) So EI EER AS «PAGS SE BGT WA ie 2 TE A EA Fee AS Haba DAE ESL IRE fap A ALB AUT FREAD CML PEAS BIS A LALA FOI: WRAL, PURE, OLA eee ee RRA FTP AR a Fh A LP A i HC SE EAR A AA HE MLS J5 PARAS ASE IIA FS FH) 6.3 fata sb IF i De i EAR AREA EA EE, AER, TEA ASE SEAM, AE, PEAR IE MLA. ARRAY TDI, HEAR RG BE BR Ab 2H Ra LOY LTA RARE RFI FE. TI, URS, SL AT AP A OR AMEE IE ACHE.220 WeResieM EEE EA 6.3.1 RARER UPR UE. ACR AS 70 g/L Np Wik. PARSE LAA, BARA BA UE. ET BE RP CER AE NBEO” , FONE HH mL AAA REM TE 1 PAM, (200ml) ty ZMH AL RATERS 10g /L. MAAR LAST LY 3% ALT LE EB AB BIR WME AO TR SARIS, HIRES Hl | RO SB 9 RAV RELES) AE. BORG AS. Serf ASR nL BLUM AA BU a9 2h oe BL BS ELA. GA AAT LS GE YT FA 70 g/L. 6.3. 2 MALIN iL) AiR HE EE SE BE i FA 7] SC se kn BE aE PE LATTA. LRTI <50X 10°/L, BRE ML OEE FA EON) Sop EAT SH Ae PE FE ESAT Fa TT a AAG AMS TE PE MRO, 6.3.3 PES AM TERNS VE MIR AN ASE T tb FEE ML AFAR Ay POUR SAFER AR SAMA, ARM. ZR ME EA A FE He BOL BE HP 24 TE TR A A JS» ET RE 5 EA 4 24 SECS), BRU, SMC AAS A REL A. A TH TNE EE EF ERS AR MIRON PON, 63.448 ASRMALV. VI. Ml, FRA RE, AP RE LES ti IT | ALA DP A PF I a EE MLS FF EAL SH TF ABR HT PE ET WE BA HARPS MOS Rt. REM OTA], AE REE BO! WAELIS: PFHAEGIKF g/L HRHAKLBA, BERR eH. (CM) RHEL IG: KEAGHAEERHAT HAR, (CH) 6.4 HPC RAS ERMA H AR AL AAS EAA, — BAS EG PE RIAU Sk ey HE — A HI AS TE AR EAR RU SG RS ART Be A SS Je AVS FE CEA LH BR BE WBE ASF eh HE FA A FEE SEMMAB. 6.4.1 SER BASE ee I. SCF PERE TA. EPEAT HMR: mS SE, OE Bh SEAM Eo BERIT 1 3ye/ (kg + min) SE PE AT A. PRA A RE TK, HPN, 2~10pg/ (ke + min) BY EBPRAIE B SEER, ARIA D> Lae AE it POOH. Fat Se WLREs AF 10pe/ Cg + min) Bt RL AL EE @ SEAR{RMSE RIIERS (2007) 221 MAA. Meee LE. 6.4.25 BMT SE WEN Bi. BSE ARTA TE DWC 38 BR, Tad PA PGK ARR A Ne Setar 5 ATMA REDE SB AS 5 AAR AERC EE A, APPILIE, 36 AUR ALIEN. U59R A 80% ~ 85% AOA FETE SURE. FE BEATA AE FL PRS eS AVNER 25 HK PL AE EI UATE AS. HSMP AREAS OT Be. ATOR If ae SORA BE LO) SR AER PERE AS IPE AGIEAT FAIA SE es ON AE HE sat» A LY TN Pe ee A FR Ag Une SLE TELS . GAS EARL, SLRRMAAS ERR LUTHER. He ERAS IN Ih EBA RB aM A.D ASR RE CE ER Bk BT A: Jin EE AL ok BAER IT: ERMATSELERA EF. TAA IEE te Ra IK MEEKLMAA, TREN DEEL BI. (EB 6.5 pe IR EARLS 9 0 > SP ES Ay PE 8, HRMS SO” EER ARAN, ONE. Zeng RIESE AS » WRU ECB SB SERIE. ME ALITY EIS. VOIR TPAPASE. Wii FRADE HEAT ABER FUP BATE ORO, AT HERE MT 8791 GaN aS AT BEE FETA RUA RA. 80% (EAA DR. BE<—15mmol/L, #ETL RIE BY 2526 | RFLRUIOEG MODS RFE TIARHVAASEPE RD, LAS REA FUMRACE 24~48 NIP PRSE IER. FET TRON 25%, 48 JI RRSLIE ES FRO IS 86.% , HUW FLMK OF 5 fl tha 42 MODS fH ab ASE BAR AE CER ET A LP AR RR a ES SEAS RRO A HT PE EIT AT PE. (ELE, RELI, IE FO, UBER PAE Lb EE WY PH TE, ARE BT. EAL TERE AL LE PA PAR AS HYSTERIA L R AAT ASU, BG, PEA MLEEAERRIT P, BRS OT RAE RA SAUL pH<7. 20°), HAELIS: HERPERY A, RARRADLRMSESAK, KE HR LR RAR 4, (DB)222 wapRiB NT NaI si veo oh a 6.6 ARF Eh a BY TR Fei HEAC SEIT, Litt ACE. RL UE SE. BEBE REARS. LG HEPC ER AEE (ORAL oa I. ue RE KAN RAR RAL. BESO Oe eRe. AR. AMON yi SE OME PAE Pt RS 5 By BRL Gk FERRE VA HG SL GE eB: BF WARAAK. (RR MAE, BDI SR Ae. ALAR AC PK eI 17 AVE AEE 6.7 hime fl FRB AAG AER A ve A PAR, RE MS. RH: TEAS HEEL ARP IG RIE R. PUBETESE a. ASR TE TELE Wea SE HY LR ANS A EE, IRA, 35°C) BP mat 1 AR AE. MESES AST TE. RNAP TE RRO"), ACS a PH i Fs «A HFG ES IN ATS FE OR. I. ZEAE OU BISBA 5 IIASA CE LE i PR AC 8 i 5 ORR, SERIE, SBA. TURAL OSH ATT REITER HEUER RMR OS | SRE GDA PE TA LEDER AS ERA SEE» (LMS BE PR LAE. AB Hef GCS PP SPLE 4~7 SP AL MMS EO BE Ae I URE rd A BI HE Pt DE 2, MSMR PIP RRS. IEF DE PEEL IY: FERMSSRMA RM RAD Rat LR, He RR Ee. (DA) 7 SPP RUS BUTTE AT bs 7.1 le RATE SPAR MAS ATE SE OR TAT DEE AT FR FEA AMR ASN PE Dy BEDS ARO" RATT. PEL Sh 28 PE SOS EAN EFL SCH BA FEI TE (1A, A HALSET EG UK 50% ~ 85.6 AME IMA EP DEI A TAS ERE» VRRP TEL IMETE. ARRAS FSET He AT PB ESS A, AEM RAR LAR. Bee EBB RTE WEA ELE ZINA HEA EL 20: NG RAR AR Fh PRS ER A REMSRARSIER (2007) 223 L, BR, KEEALAWAR AR. (DM) 7.2 Bak SRE AAS FLL 4. 5L/Gmin +m?) CRE > 600m1/(min +m?) KR WHRE>170m1/Cmin +m?) fy CF 08 ti 2S SEE AS 9 PA SO EVR), RTT, Aa EFC Ak HER EAR ED ER Os A EEE, TERE BLD a BRL TAIT Ds BUA IE BLA RE TET RBA RT FEA SE. ATH LAW, BHP Lae A, > FA, PBL. Bede FT Py — 4 US A HAS ER 7.3 TRG AKA (SvO,) SvOe FA AEAG ATR BR SAR, PETA be BERETS OE AU HF 4S. River UU NRE ARE TRAN. AERO FE Aa RZ SvO, TEAK ML AEE TEP DESEO TES. PRICDISb. BR“ SvO. 5 SLAB. DO. AFT BRIBE DH FF Hy 2 ERR AN BEBE 7.4 it $l aR MOLPL ASRS A ESSERE TG AEG AEA EIA BY BU ASE, PERK FILA CAmmol/L) BURIALS BU AR EO, aM PLB RA Le Be LPO A eB 2 WA), DLR TE A PE SR dR MAP AUREL. HEFL, DO,. VO, #1 CI, php 3 oh FLA Ye HE TE HE (<2mmol/L) AbRHE, IAT — AP 24 AD tot aM PL RH ER TE << 2mmol/L) BYE, FELINE PY FLARE ETE a AA, TE LPR OD TAL. AHA FPSB ABS, AER 21, AR Sa LAR MEH OO BE Hoe LAR A A Ha EK RPAH BUA, LRMR MH BRA RE. (CD 7.5 BURA ABER AS AY JSR A SH AO BE PRE. RRR PTS = AEE). IE (—2~—Smmol/L), PKE (—5~—15mmol/L), HEF (<—15mmol/L.), FRR AACE 5 BD — A 24 Ati A AM PRCA FERAL» AS HE MACE H.R RA I TT LPP TE AS ISA RE SE224 lem Bie ee FPPEM ML. BTA EO, RB SAI AR. Be {adi SPUD OBE FE KBR: URE A (ALRRAIK, MODS 2246. 56 TFS AE LEY LEAS. TEDSTER HAEL 2, RAMKES MSW, LAM ADAMM, (BA) 7.6 HRW pH (pHi) #8 @RA CO: A (PgCOz) pHi ERAT ABA AUR AS. AEA ESA RTI AY Ba AE, CA BEFELE SE PeOO; tt pHi ay $80, SFP, PeCO,>PaCO,. P (g-a) CO, 25 AV SORIA KU, PeCO, IEF H<6. 5kPa, P (ga) CO, EH {A<1.5kPa, PgCO, ak P (ga) CO; HRA, JRL. pHi SIAID-7. 30 PPA. IFLA PRL AGHRT TE] C24 ovat 5 TE HTH EY ERR RAD, (EL Ee AHS AEE, BTL RUIN A HOSE TSA MODS AY 24"), Rit, EE — THT BS TE. SHORE, SAK TIES FS LA LE SIKH PAAR oe CHEE ARE A. GR AE. MODS: BRAS, BURGH UN A) ALE Be RIZE PA ESTP ERE OM 7.7 Be EBB. BEF S21 25 AOL PE PAST FD BE JB A LK 9 ZEBE BEE BGR AIIM GE 5 EATS NCAT BL A SAE ALG yO PRA CH SOE EE Bl AE OF, TEE, RE IR ROR EG HOPPE A SUG RITE. 8 PETA EA LY PEM SE AH) HL I FS ALPE HE AAR LAE EA SE — APPR, LP i FOE, MH. SRE. KAA AT. RO. BUT ASE) TARE a HELE Ee AS 5 ACE cd IL SF a PE A IA BEC GIS FE See ACHR A AL SPSS HEA EE AR ALA BE BRE RAEI CUES. » Fe aL PE AR oe AC aH at BE SOG | AE, BEML OV ACRE s LR TTES I + MAE PETE AA Ea AB | aE ws SEAR, ZC AA BRIG, WRAL, JR AOE MIE I. ACHE PETITE ASO CHES SLR). BILE aI He MLE ATL PA eH OK CESS FO EO AE FE SF A EF BE BEA AB HSE BSCMS BARRAIER (2007) 225 FEATRIPE OS. Py Bee], BLL PERU SE I OT RARE EH AES IE REET 101 AVAIE HORE [BUPA SA SF AM AERS IGT ARS HI OY OAR LEA SC FE<90mmHg) EPR ANTE aE YB, RUZ SE SRA TET Be SS RS. SEP Wee ae aces ESE PEE, REMI MRCAS PE RRR ye oe eB ROY TEER ADR PE AE AS Hl ot a A Sa EEA, IS I BE 1 5 FSS BES I GA), 5} AE te a IBERIA RAE TEZE 70 BR 100mmHg IFAT ASE, HERE FEF TIE SHAT IRD. RAN CHUM 1996, SET 5196). Ra ME PRREREAUTE ISP AY Dr TE HEB Ha ee SER Ay 9 a PR th BT LOOrmmHg!), 5 Yb. ARRAY EAS HR SE I HO Sak Be PE IY IS 2 (SA IE 8 BERRI | PAE BYE ARASH HL ASR MLPA SE, AES RAR TE AL) EAC 2 2S EL HE AREAL AERA MEA, BAS RLU, PEA a RA SYRIA. ARTI. HAAR APR AY Ke ML EAC, ALY SE GU Us ARG til, TBR st AG A. ST PRIMA Oa A. Aes ANA OIE TAR A SAR BER SEES A I 5 J POA PA HIT ALA EP OR «SUD TCE AS A SA AA EA AE. ek AUR. A, a Ot Ae NE if Ha ML PERSIA BRIAR CLAP LS» DORE LP PRE PERS 1B). HPC HORE EE TE KOPF, DIGRGIERR EEE. PAR AE Be gO) Fee HAIR FE AE SEIS A TAF, LEAT a BA tN BRERI3: HEAR AO ARLBA, PMR AAA SBMA A 80~90mmHg, VRE SRBREORARIE, HARV R aes Hh ARAGALARBEELR, DA) | HEEL: SOMME SRG BA, SPRARRARBAR BLEMALR, (ER) 1G HEE RHE RA (2007)) 2B fe eR GEE K&B AR) WA FR BSR Hkh ® 2 RSH Bak226 WRITS Hi BX MR 1. Ronald D Miller. Miller’ s Anesthes: stone, 2006; 1777-1807. 2. MBIT ER, RENE. ARON TEAR Se I ARE RS. DS BR i $s SLE A 1998. 19 (2); 68-70. 3. Shoe of survivors as therapeutic goals in high risk surgical patients. Chest, 1988, 94 (6): 1176-1186. 4. Hayes MA, Timmins AC, Yau E, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med, 1994, 330 (24); 1717-1722. Lobo SMA, Salgado PF, Castillo VGT, et al. Effects of maximizing oxygen delivery 6th ed. New York: Elsevier/churchill living aker WC. Appel PL, Kram HB, et al. Prospective trial of supranormal values. on morbidity and mortality in high risk surgical patients. Crit Care Med, 2000, 28 (10): 3396-3404. 6. Brill SA, Stewart TR, Brundage SI, et al. Base deficit does not predict mortality sec~ ondary to hyperchloremic acidosis. Shock, 2002, 17 (6): 459-462. 7. Goldberg LI. Dopamine; Clinical use of an endogenous catecholamine. N Engl J meds 1974, 291 (14); 707-710. 8. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest, 1989, 95 (2 Suppl): 25-48. 9. Weil MH, Shubin H, Carlson R. Treatment of circulatory shock. Use of sympathomi- tive agents. JAMA, 1975, 231 (12); 1280-1286. Cottingham, Christine A. Resuscitation of Traumatic Shock: A Hemodynamic Re view. AACN Advanced Critical Care. 2006, 17 (3); 317-326. 11. Singhal R, Coghill JE, Guy A, et al. Serum lactate and base deficit as predictors of mortality after ruptured abdominal aortic aneurysm repair. , 2005, 30 (3); 263-266. metic and related vas 10. 12. Abramson D, Scalea TM, Hitchcock R, et al. Lactate clearance and survival follow- ing injury. ] Trauma, 1993, 35; 584-589. 13. Manikis P, Jankowski S, Zhang H, et al. Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am J Emerg Med, 1995, 13: 619-622. 14. Rixen D, Base deficit development and its prognostic significance in posttrauma critical illness: an analysis by the trauma registry of the Deutsche Gesellschaft unfallchirurgie, Shock, 2001, 15: 83-89. . Rutherfor EJ. Base deficit stratifies mortality and determines therapy. J Trauma, 1992, 33: 417-423. 16. Kasuya H, Onda H, Yoneyama T, et al. Bedside monitoring of circulating blood vol-17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 29. 30. 3h. ARMS MR ORANG (2007) 227 ume after subarachnoid hemorrhage. Stroke, 2003, 34 (4): 956-960. Cropp GJ. Changes in blood and plasma volumes during growth. J Pediatr, 1971, 78 (2); 220-229, American College of Surgeons Committee on Trauma, Advanced Trauma Life Support for Doctors. Student course manual. 6th ed. Chicago; American College of Surgeonsy 1997, 103-112, Tintinalli JE, Kelen GD, Stapezynski JS. Emergency Medicinea Comprehensive Study Guide. Fifth Edition. Tianjin Science and Technology Press. 2001, 215-250. Bongard FS, Sue DY. Current Critical Diagnosis 8 Treatment, Second Edition. People’s Medical Publishing House, 2003, 242-267. Marzi L. Hemorrhagic shock: update in pathophysiology and therapy. Acta Anaesthe- siol Scand Suppl. 1997, 111, 42-44. Heckbert SR, Vedder NB, Hoffman W, ct al. Outcome after Hemorrhagic shock in trauma patients. J Trauma, 1998, 45 (3); 545-549. RAPHE, DL. PARAS, 2000, 16 (7); 446-447. Yao YM, Tian HM, Sheng ZY, ct al. Inhibitory effects of low-dose polymyxin B on hemorrhage-induced endotoxin bacterial translocation and cytokine formation. J Trau- ma, 1995, 38 (6); 924-930, BIG DL. TURRAL. ERE ET RRR AE BUCA IT . IE. A ROEBE MEAL, 2001, 35-72. Frederic S. Bongard Shock and resuscitation Current Critical Care Diagnosis and Treat- ment, Second Edition, 2002. - Bishop MH, Shoemaker WC, Appel PL» et al. Prospective, randomized trial of sur- vivor values of cardiac index, oxygen delivery, and oxygen consumption as resuscita- tion endpoints in severe trauma. ] Trauma, 1995, 38: 780-787. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Eng J Med, 1994, 330; 1717-1722 Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med, 1995, 333: 1025-1032. McKinley BA, Kozar RA, Cocanour CS, et al. Normal versus supranormal oxygen delivery goals 825-832. Kern JW, Shoemaker WC. Meta-analysis of hemodynamic optimization in high-risk patients. Crit Care Med, 2002, 30; 1686-1692. in shock resuscitation: the response is the same. J Trauma, 2002, 53: + Stern S, Dronen SC, Birrer P, et al. Effect of blood pressure on hemorrhage volume and survival in a near-fatal hemorrhage model incorporating a vascular injury. Ann Emerg Med, 1993, 22: 155-163.228 Were Sie Fa 33. Burris D, Rhee P, Kaufinan C, et al. Controlled resuscitation for uncontrolled hem- orrhagic shock. J Trauma, 1999, 46; 216-223. 34. Asensio JA, Meduflie L, Petrone P, et al. Reliable variables in the exsanguinated pa tient which indicate damage control and predict outcome. Am J Surg, 2001, 182: 743-751. Childs EW, Udobi KF, Hunter FA. Hypothermia Reduces Microvascular Permeabili- ty and Reactive Oxygen Species Expression after Hemorrhagic Shock. J trauma. 2005, 58 (2), 271-277, 36. Tisherman SA. Hypothermia and injury.Curr Opin Crit Care, 2004, 10 (6): 512-519. . Ornstein E, Eidelman LA, Drenger B, et al. Systolic pressure variation predicts the Jin Anesth, 1998, 10; 137-140. 38. Liu SQ, Qiu HB, Yang Y, et al. Assessment of stroke volume variation and in response to acute Blood loss. J trathoracic blood volume index on the responsiveness to volume loading in mechanical- ly ventilated canine with hemorrhagic shock. Zhonghua Wai Ke Za Zhi, 2006, 44 (17); 1216-1219. 39. Sakka SG, Meier-Hellmann A. Extremely high values of intrathoracic blood volume in critically ill patients. Intensive Care Med, 2001, 27 (10); 1677-1678. 40. Severinghus JW. Spellman MJ. Pulse oximeter failure thresholds in hypotension and vasoconstriction. Anesthesiology, 1990, 73; 532-537. 41. Cassidy C, Marcher J. Base deficit: an indicator of tissue hypoperfusion. Int J ‘Trauma Nurs, 1995, 1 (4): 108-112. 42, Englehart MS, Schreiber MA. Measurement of acid-base resuscitation endpoint tate, base deficit, bicarbonate or what? Curr Opin Crit Care, 2006, 12 (6): 569-574. 43, Hayes MA, Yau EH. Response of critically ill patients to treatment aimed at achie~ ving supranormal oxygen delivery and consumption. Relationship to outcome. Chest. 1993, 103 (3): 663-664. 44. Pearse RM, Hinds CJ. Should we use central venous saturation to guide management in high-risk surgical patients? Crit Care, 2006, 10 (6): 181. 45. Moomey CB, Melton SM, Croce MA, et al. Prognostic value of blood lactate, base deficit, and oxygen-derived variables in LDS50 model of penetrating trauma. Crit Care. Med, 1999, 27 (1); 154-161. 46. McNelis J, Marini CP, Jurkiewiez A, et al. Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit. Am J Surg, 2001, 182: 481-485. 47. Robbins MR, Smith RS, Helmer SD. Serial pHi measurement as a predictor of mor-18. 49. 51. 52. 53. 5A. 55. 56. 57. 58. 59. 60. 61. MEMO AIERA (2007) 229 tality. organ failure, and hospital stay in surgical patients. Am Surg, 1999, 65 (8): 715. McKinley BA, Parmley CL, Butler BD. Skeletal muscle POz» PCO:, and pH in hemorrhage, shock, and resuscitation in dogs. J Trauma, 1998, 44; 119-127. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med, 1999, 340; 409-417, Zebrabchi, S ocrit measurements in identifying major injury in adult trauma patients. Injury, 2006, 37 (1), 46-52. Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of thrombelastography in nert R, Goldman M, et al. Diagnostic performance of serial haemat- assessment of trauma patient coagulation. J Trauma, 1997, 42 (4): 716-720. Jackson MR, Olson DW, Beckett WC, et al. Abdominal vascular trauma: a review of 106 injuries. Am Surg, 1992, 58; 622-626. Blocksom JM, Tyburski JG, Sohn RL, et al. Prognostic determinants in duodenal in- juries. Am Surg, 2004, 70; 248~ Ertel W. Eid K, Keel M, et al. Therapeutical strategies and outcome of polytrauma- tized patients with pelvic injuries. A six-year experience. Eur J Trauma, 2000, 261 278-286. Hill DA, West RH, Roncal S. Outcome of patients with haemorrhagic shock: an in~ dicator of performance in a trauma centre. J R Coll Surg Edinb, 1995, 40; 221-224. Hoyt DB, Bulger EM, Knudson MM, et al. Death in the operating room: an analy- sis of a multi-center experience. J Trauma, 1994, 37; 426-432. Johnson JW, Gracias VH, Schwab CW, et al. Evolution in damage control for ex- sanguinating penetrating abdominal injury. J Trauma, 2001, 51: 261-269. Farahmand Ny Sirlin CB, Brown MA, et al. Hypotensive patients with blunt abdom- inal trauma; performance of screening US. Radiology, 2005, 2351 436-443. Wherrett LJ, Boulanger BR, McLellan BA, et al Hypotension after blunt abdominal trauma; the role of emergent abdominal sonography in surgical triage. J Trauma, 1996, 41; 815-820, Liu M, Lee CH, P’Eng FK. Prospective comparison of diagnostic peritoneal lavage, computed tomographic scanning, and ultrasonography for the diagnosis of blunt ab- dominal trauma, J Trauma, 1993, 35; 267-270. Rozycki GS, Ballard RB, Feliciano DV, et al. Surgeon performed ultrasound for the assessment of truncal injuries; lessons learned from 1540 patients. Ann Surg, 1998, 228 557-567.230 mE SRE 62. 63. 64. 66. 67. 68. 69. 10. 7, 72. 73. mA 75. 76. Lindner T, Bail HJ, Manegold S, et al. Shock trauma room diagnosis; initial diag- nosis after blunt abdominal trauma. A review of the literature. Unfallchirurg. 2004, 107; 892-902. Kaye AD, Grogono AW. Fluid and electrolyte physiology. Anesthesia, 5th ed, Philadelphia: Churchill Living stone, 2000, 1601-1612. Scheingraber S, Rehm M, Sehmisch C. Rapid saline infusion produces hyperchloremie acidosis in patients undergoing gynecologic surgery. Anesthesiology, 1999, 90: 1247-1249. . Healey MA, Davis RE, Liu FC, et al. Lactated Ringers is superior to normal saline in a model of massive hemorrhage and resuscitation. J Trauma, 1998, 45; 894- 898. Waters JH, Miller LR, Clack S, et al. Cause of metabolic acidosis in prolonged sur gery. Crit Care Med, 1999, 27; 2142-2146. Velasco IT, Pontieri V, Rocha-e-Silva M, et al. Hyperosmotic NaCl and severe hem- orrhagic shock. Am J Physiol, 1980, 239; H664-H673. Holeroft J, Vassar M, Turner JE, et al. 3% NaCl and 7. 5% NaCl dextran for resus- citation resuscitation of severely injured patients. Ann Surg, 1987, 206; 278-288. Rocha-e-Silva M, Figueiredo LFP. Small volume hypertonic resuscitation of circulato- ry shock. Clinies, 2005, 60, 159-172. Wade CE, Kramer CG, Grady JJ, et al. Efficacy of hypertonic 7.5% saline and 6% dextran-70 in treating trauma; A meta-analysis of controlled clinical studies. Surgery; 1997, 122; 609-616. Matteucci MJ, Wisner DH, Gunther RA, et al. Effects of hypertonic and isotonic fluid infusion on the flash evoked potential in rats; Hemorrhage, resuscitation, and hypernatremia. ] Trauma, 1993, 34; 1-7. Kien ND, Kramer GC. Cardiac performance following hypertonic saline. Braz ] Med Biol Res, 1998, 22; 2245-2248, Rizoli SB, Rhind SG, Shek PN, et al. The Immunomodulatory Effects of Hypertonic Saline Resuscitation in Patients Sustaining Traumatic Hemorrhagic Shock A Random- ized, Controtled. Double-Blinded Trial. Ann Surg, 2006, 243; 47-57. Wade C, Grady J. Kramer G, et al. Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. J Trauma, 1997, 42 (Suppl); S61-S65. Sheikh A, Matsuoka T, Wisner D. Cerebral effects of resuscitation with hypertonic saline and a new low-sodium hypertonic fluid in hemorrhagic shock and head inju- ry. Crit Care Med, 1996, 24: 1226-1232. Simma B, Burger R, Falk M, et al. A prospective, randomized, and controlledMBB AFEMINEA (2007) 231 7. 78. 79. 80. 81. 82, 83. 84. 86. 87. 88. 89. 90. 91 study of fluid management in children with severe head injury: Lactated Ringer’ so- lution versus hypertonic saline. Crit Care Med, 1998, 26; 1265 -1270. Dubick MA, Zaucha GM, Korte DW, et al- Acute and subacute toxicity of 7.5% hy- pertonic saline-6% dextran-70 (HSD) in dogs 2 Biochemical and behavioral respon- ses.J Appl Toxicol, 1993, 13; 49-58. Dubick MA, Wade CE. A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and in humans. J Trauma, 1994, 36; 323-330. Shackford SR, Bourguignon PR, Wald SL, et al. Hypertonie sali patients with head injury; @ prospective, randomized clinical trial. J Trauma, 1998, 44, 50-58. Vercueil A, Grocott MP, Mythen MG. Physiology, pharmacology, end rationale for e resuscitation of colloid administration for the maintenance of effective hemodynamic stability in criti- cally ill patients. Transfus Med Rev, 2005, 19: 93-109. Treib J, Haass A, Pindur G, et al. All medium starches are not the same; influ- ence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma vol- ume, Hemorrhagic conditions. and coagulation. Transfusion, 1996, 36 (5): 450- 455. Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacoki- net, 2005, 44; 681-699. Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg, 2004, 139; 552-563. Baron JB. Adverse effects of colloids on renal function. In; Vincent JL. Yearbook of intensive care and emergency medicine. Berlin; Springer, 2000, 486-493. . Treib J, Baron JF, Grauer MT, et al. An international view of hydroxyethyl star- ches. Intensive Care Med, 1999, 25; 258-268. Warren BB, Durieux ME. Hydroxyethyl starch; Safe or not? Anesth Analg, 1997, 84; 206-212. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch, Thromb Haemost, 1997, 78: 974-983. Deusch E, Gamsjager T, Kress HG, et al. Binding of hydroxyethyl starch molecules to the platelet surface, Anesth Analg, 2003, 97; 680-683. Madidpour C, Dettori N, Frascarolo P, et al. Molecular weight of hydroxyethyl starch; Is there an effect on blood coagulation and pharmacokinetics? Br J Anaesth, 2005, 94; 569-576. Bork K. Pruritus precipitated by hydroxyethyl starch: A review. Br J Dermatol, 2005, 152; 3-12, . Y.Sakr1, DPayen, K Reinhartl, et al. Effects of hydroxyethyl starch administration232 BROTHER Be REA 92. 93. 94. 96. 97. 98. 99. 100. 101. 102, 103. on renal function in critically ill patients Br J Anaesth, 2007, 98: 216-224. Entholzner EK, Mielke LL, Calatzis AN, et al. Coagulation effects of a recently de~ veloped hydroxyethyl starch (HES 130/0. 4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand, 2000, 44; 1116-1121. Langeron O, Doelberg M, Ang ET, ct al. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0. 4), causes fewer effects on coagulation in major or- thopedie surgery than HES 200/0. 5. Anesth Analg, 2001, 92; 855-862. Jungheinrich C, Sauermann W, Bepperling F, et al. Volume efficacy and reduced in- fluence on measures of coagulation using hydroxyethyl starch 130/0. 4 (64) with an optimised in vivo molecular weight in orthopaedic surgery: a randomized, double blind study. Drugs RD, 2004, 5 (1): 1-9. . Haisch G, Boldt J, Krebs C, et al. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (626 HES 130/0. patients undergoing major abdominal surgery. Anesth Analg, 2001, 92 (3): 565- s71. Michael PW, Grocott BM, Mythen MG, et al. Perioperative Fluid Management and Clinical Outcomes in Adults. Anesth Analg, 2005, 100; 1093-1106 Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solu- tions in patients with hypovolemic and septic shock. Crit Care Med, 1983, 11s 839-850. Choi PT, Yip G, Quinonez L, et al. Crystalloids versus colloids in fluid resuscita~ tion: a systematic review. Crit Care Med, 1999, 27; 200-210. ) on coagulation in Schierhout G, Roberts 1. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients; a systemic review of randomized trials. BMJ, 1998, 316; 916-964. Alderson P, Schierhout G, Roberts I, et al, Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev, 2000, 2, CD000567. Roberts I, Alderson P, Bunn F, et al, Colloids versus crystalloids for fluid resusei~ tation in critically ill patients, Cochrane Database of Systematic Reviews 2004, Issue 4. No. CD000567, DOT; 10. 1002/14651858. CD000567. pub2. Cochrane Injuries Group. Human albumin administration in critically ill patients; Systematic review of randomized controlled trials. BMJ, 1998, 317; 235-240. Vincent JL, Dubois MJ, Navickis RJ. et al. Hypoalbuminemia in acute illness; Is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg, 2003, 237: 319-334.106. 107. 108. 109. 110. lu. 112, 113. 116. 117. 118. 119. 120. 121, 122. . The SAFE Study Investigators. A comparison of albumin and saline for fluid resus . Rizoli SB. Crystalloids and colloids in trauma resuscitation: {MS RARBIISR (2007) 233 tation in the intensive care unit. N Engl J Med, 2004, 350; 2247-2256. a brief overview of the current debate. J Trauma, 2003, 54 (5); S82-S88. Kelley DM, CEN MR. Hypovolemie Shock. Crit Care Nurs Q. 2005, 28 (1); 2-19, Weil MH, Henning RJ. New concepts in the diagnosis and fluid treatment of circula- tory shock. Anesth Analg, 1979, 58; 124-132. Jean-Louis Vincent, Max Harry Weil. Fluid challenge revisited. Crit Care Med, 2006, 34 1337, Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 2004, 32; 858- 873, Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: hemorrhagic shock, Crit Care, 2004, 8 (5); 373-381. Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock se verity, is associated with worse outcome in trauma. J Trauma, 2003, 54 (5); 898. THES. UPR MEE ARIE, 2000. EN, THE, ERE. ORR AR SOL TEIR A OA OE | Sir ARes, 2004, 17 (6): 440-441. |. Gonzalez EA, Moore FA, Holcomb JB. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. ] Trauma, 2007, 62 (1); 112-119. . Ho AM, Dion PW, Cheng CA. A mathematical model for fresh frozen plasma trans- fusion strategies during major trauma resuscitation with ongoing hemorrhage. Can J Surg, 2005, 48 (6); 470-478. Ledgerwood AM, Lucas CE. A review of studies on the effects of hemorrhagic shock and resuscitation on the coagulation profile.] Trauma, 2003, 54 (5 Suppl): S68-S74. Lucas CE, Ledgerwood AM, Saxe JM. Plasma supplementation is beneficial for coagu- lation during severe hemorrhagic shock. Am J Surg, 1996, 171 (4), 399-404. Domsky ME. Hemodynamic resuscitation. Crit Care Clin, 1993, 10 (4); 715-726. ACOG Educational Bulletin, American College of Obstetricians and Gynecologists. Hemorrhagic shock. Int J Gynaecol Obstes, 1997, 57 (2); 219-226. Hilbernan M, Maseda J, Stinson EB, et al. The diuretic properties of dopamine in patients after open-heart operations. Anesthesiology, 1984, 61; 489. Bon Khalil. Hemodynamic responses to shock in young trauma patient: Need for in- vasive monitoning. Crit Care Med, 1994, 22; 633-639. Scalea TM. Resu itation of multiple trauma and heat injury: Role of crystalloid flu-